



(51) International Patent Classification:

A61K 31/44 (2006.01) C07D 401/14 (2006.01)

(21) International Application Number:

PCT/US2019/047423

(22) International Filing Date:

21 August 2019 (21.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/721,214 22 August 2018 (22.08.2018) US

(71) Applicant: ENANTA PHARMACEUTICALS, INC.

[US/US]; 500 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors: **HE, Jing**; 21 Cedar Ave, Somerville, MA 02143 (US). **GRANGER, Brett**; 1 Lillian Avenue, Sudbury, MA 01776 (US). **WANG, Guoqiang**; 65 Beckett Road, Belmont, MA 02478 (US). **OR, Yat Sun**; 29 Michaelchris Drive, Waltham, MA 02452 (US).

(74) Agent: **HARLAN, Edgar W.** et al.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF



(I)

(57) Abstract: The present invention discloses compounds of Formula (I), Formula (I) and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).



CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF

RELATED APPLICATIONS

5 This application claims the benefit of U.S. Provisional Application No. 62/721,214, filed on August 22, 2018. The entire teachings of the above applications are incorporated herein by reference.

TECHNICAL FIELD

10 The present invention relates generally to compounds and pharmaceutical compositions useful as ASK-1 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of ASK-1 and methods for their preparation and use.

BACKGROUND OF THE INVENTION

15 Apoptosis signal-regulating kinase 1 (ASK-1) is a member of the mitogen-activated protein kinase kinase kinase (MAPKKK, MAP3K) family, which when activated phosphorylates downstream MAP kinase kinases (MAPKK, MAP2K), which in turn activate MAP kinases (MAPK). MAPKs elicit a response by phosphorylating cellular substrates, thus regulating the activity of transcription factors that ultimately control gene expression.

20 Specifically ASK-1, also known as MAPKKK5, phosphorylates MAPKK4/MAPKK7 or MAPKK3/MAPKK6, which subsequently phosphorylates and activates the c-Jun N-terminal protein kinase (JNK) and p38 MAPKs, respectively (H. Ichijo, et al., *Cell Comm. Signal* **2009**, 7, 1-10; K. Takeda, et al., *Annu. Rev. Pharmacol. Toxicol.* **2008**, 48, 199-225; H. Nagai, et al., *J. Biochem. Mol. Biol.* **2007**, 40, 1-6). Activation of the JNK and p38 pathways

25 triggers a downstream stress response such as apoptosis, inflammation, or differentiation (H. Ichijo, et al., *Science* **1997**, 275, 90-94; K. Takeda, et al., *J. Biol. Chem.* **2000**, 275, 9805-9813; K. Tobiume, et al., *EMBO Rep.* **2001**, 2, 222-228; K. Sayama et al., *J. Biol. Chem.* **2001**, 276, 999-1004).

 The activity of ASK-1 is regulated by thioredoxin (Trx), which binds to the N-
30 terminal end of ASK-1 (M. Saitoh, et al., *EMBO J.* **1998**, 17, 2596-2606). ASK-1 is activated succeeding autophosphorylation at Thr838 in response to environmental stimuli including oxidative stress, lipopolysaccharides (LPS), reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, an increase in cellular calcium ion concentrations, Fas ligand, and various cytokines such as tumor necrosis factor (TNF) (H. Nishitoh, et al., *Genes Dev.* **2002**,

16, 1345-1355; K. Takeda, et al., *EMBO Rep.* **2004**, *5*, 161-166; A. Matsuzawa, et al., *Nat. Immunol.* **2005**, *6*, 587-592).

ASK-1 has been associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease, metabolic disorders, and acute and chronic liver diseases (R. Hayakawa, et al., *Proc. Jpn. Acad., Ser. B* **2012**, *88*, 434-453).

More specifically, ASK-1 has been associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis (NASH). In a mouse model, high fat diets have caused induction of hepatic steatosis, ultimately causing fat accumulation and fatty acid oxidation. This led to the generation of ROS which caused hepatocyte dysfunction and death (S. K. Mantena, et al., *Free Radic. Biol. Med.* **2008**, *44*, 1259-1272; S. K. Mantena, et al., *Biochem. J.* **2009**, *417*, 183-193). Moreover, TNF was shown to be critical for apoptosis of hepatocytes through the ASK-1-JNK pathway, and TNF deficient mice showed reduced hepatic steatosis and fibrosis (W. Zhang, et al., *Biochem. Biophys. Res. Commun.* **2010**, *391*, 1731-1736).


Small molecule compounds which act as ASK-1 inhibitors have been disclosed in the following publications: WO 2008/016131, WO 2009/027283, WO 2009/0318425, WO 2009/123986, US 2009/0318425, WO 2011/041293, WO 2011/097079, US 2011/0009410, G.P. Volynets, et al., *J. Med. Chem.* **2011**, *54*, 2680-2686, WO 2012/003387, WO 2012/011548, WO 2012/080735, Y. Terao, et al., *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7326-7329, WO 2013/112741, G.P. Volynets, et al., *Eur. J. Med. Chem.* **2013**, *16*, 104-115, US 2014/0018370, WO 2014/100541, WO 2015/095059, WO 2016/049069, WO 2016/049070.

There is a need for the development of ASK-1 inhibitors for the treatment and prevention of disease. The present invention has identified compounds which inhibit ASK-1 as well as methods of using these compounds to treat disease.

SUMMARY OF THE INVENTION


The present invention relates to compounds and pharmaceutical compositions useful as ASK-1 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of ASK-1 and methods for their preparation and use. In addition, the present invention includes the process for the preparation of the said compounds.

In its principal aspect, the present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof:




wherein

R¹ is an optionally substituted heteroaryl, preferably an optionally substituted 5-membered heteroaryl, such as one of the groups below:



wherein R₄ is selected from the group consisting of:

- 1) Hydrogen;
- 2) Optionally substituted -C₁-C₈ alkyl;
- 3) Optionally substituted -C₂-C₈ alkenyl;
- 10 4) Optionally substituted -C₂-C₈ alkynyl;
- 5) Optionally substituted -C₃-C₈ cycloalkyl;
- 6) Optionally substituted aryl;
- 7) Optionally substituted arylalkyl;
- 8) Optionally substituted heterocycloalkyl;
- 15 9) Optionally substituted heteroaryl; and
- 10) Optionally substituted heteroarylalkyl;



X² and X³ are each independently selected from N or C(R⁵);

R⁵ and R⁶ are each independently selected from the group consisting of:

- 20 1) Hydrogen;
- 2) Halogen;
- 3) -NO₂;
- 4) Cyano;
- 5) Optionally substituted -C₁-C₈ alkyl;
- 25 6) Optionally substituted -C₃-C₈ cycloalkyl; and
- 7) Optionally substituted 3- to 8- membered heterocycloalkyl;

X¹ is N or C(R¹¹), R¹¹ is hydrogen, halogen or optionally substituted alkoxy;

$\textcircled{\text{B}}$ is selected from $\text{—C}_3\text{—C}_8$ cycloalkyl and $\text{—C}_4\text{—C}_8$ cycloalkenyl, preferably cyclopropyl, cyclobutyl, cyclopentenyl or cyclohexenyl, each of which is optionally substituted with one or more substituents which are not R^3 ;

R^2 is selected from the group consisting of:

- 1) Hydrogen;
- 2) Halogen;
- 3) —NO_2 ;
- 4) Cyano;
- 5) Optionally substituted $\text{—C}_1\text{—C}_8$ alkyl;
- 6) Optionally substituted $\text{—C}_2\text{—C}_8$ alkenyl;
- 7) Optionally substituted $\text{—C}_2\text{—C}_8$ alkynyl;
- 8) Optionally substituted $\text{—C}_3\text{—C}_8$ cycloalkyl;
- 9) Optionally substituted aryl;
- 10) Optionally substituted arylalkyl;
- 11) Optionally substituted 3- to 8- membered heterocycloalkyl;
- 12) Optionally substituted heteroaryl;
- 13) Optionally substituted heteroarylalkyl;
- 14) $\text{—N(R}^7\text{)(R}^8\text{)}$;
- 15) $\text{—S(O)}_2\text{N(R}^7\text{)(R}^8\text{)}$;
- 16) $\text{—N(R}^7\text{)C(O)(R}^8\text{)}$; and
- 17) $\text{—N(R}^7\text{)S(O)}_2\text{(R}^8\text{)}$;

R^3 is selected from the group consisting of:

- 1) —NO_2 ;
- 2) Cyano;
- 3) $\text{—N(R}^7\text{)(R}^8\text{)}$;
- 4) $\text{—N(R}^9\text{)C(O)N(R}^7\text{)(R}^8\text{)}$;
- 5) $\text{—N(R}^7\text{)C(O)(R}^8\text{)}$;
- 6) $\text{—N(R}^7\text{)C(O)}_2\text{(R}^8\text{)}$;
- 7) $\text{—N(R}^9\text{)S(O)}_2\text{N(R}^7\text{)(R}^8\text{)}$;
- 8) $\text{—N(R}^7\text{)S(O)}_2\text{(R}^8\text{)}$;
- 9) $\text{—C(O)}_2\text{(R}^7\text{)}$;
- 10) $\text{—C(O)N(R}^7\text{)(R}^8\text{)}$;
- 11) $\text{—C(O)N(R}^7\text{)S(O)}_2\text{(R}^8\text{)}$;

- 12) $-\text{CH}_2(\text{O})\text{C}(\text{O})_2(\text{R}^7)$;
- 13) $-\text{CH}_2(\text{O})\text{C}(\text{O})\text{N}(\text{R}^7)(\text{R}^8)$;
- 14) Optionally substituted $-\text{C}_1\text{-C}_8$ alkyl;
- 15) Optionally substituted $-\text{C}_2\text{-C}_8$ alkenyl;
- 5 16) Optionally substituted $-\text{C}_2\text{-C}_8$ alkynyl;
- 17) Optionally substituted $-\text{C}_3\text{-C}_8$ cycloalkyl;
- 18) Optionally substituted aryl;
- 19) Optionally substituted arylalkyl;
- 20) Optionally substituted 3- to 8-membered heterocycloalkyl;
- 10 21) Optionally substituted heteroaryl; and
- 22) Optionally substituted heteroarylalkyl;

wherein R^7 , R^8 , and R^9 are independently selected from the group consisting of hydrogen, $-\text{C}_1\text{-C}_8$ alkyl, $-\text{C}_3\text{-C}_8$ cycloalkyl, 3- to 8- membered heterocycloalkyl, aryl, and heteroaryl, all of which are optionally substituted with 1-3 substituents selected from halo, alkyl, mono- or
 15 dialkylamino, alkyl or aryl or heteroaryl amide, $-\text{CN}$, alkoxy, $-\text{CF}_3$, aryl, and heteroaryl. Alternatively, R^7 and R^8 are taken together with the nitrogen to which they are attached to form a heterocyclic.

In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or combination of compounds
 20 of the present invention, or a pharmaceutically acceptable salt form, stereoisomer, solvate, hydrate or combination thereof, in combination with a pharmaceutically acceptable carrier or excipient.


In another embodiment, the present invention provides a method for the prevention or treatment of an ASK-1 mediated disease or condition. The method comprises administering a
 25 therapeutically effective amount of a compound of Formula (I). The present invention also provides the use of a compound of Formula (I) for the preparation of a medicament for the prevention or treatment of an ASK-1 mediated disease or condition. Such diseases include autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease, metabolic disorders, and acute and chronic liver diseases.

DETAILED DESCRIPTION OF THE INVENTION

A first embodiment of the invention is a compound represented by Formula (I) as described above, or a pharmaceutically acceptable salt or ester thereof.

In certain embodiments, the present invention relates to compounds of Formula (I),


and pharmaceutically acceptable salts and esters thereof, wherein $\textcircled{\text{A}}$ is selected from:




wherein each of the above shown groups is optionally substituted when possible, and each R⁵ and R⁶ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I),


and pharmaceutically acceptable salts and esters thereof, wherein $\textcircled{A}$ is



In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, wherein R₁ is selected from the groups below:




and R^4 is selected from:



wherein each of the above shown groups is optionally substituted.


In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, wherein R^2 is selected from the groups below:



wherein each of the above shown groups is optionally substituted.

In certain embodiments, the present invention relates to compounds of Formula (I),


and pharmaceutically acceptable salts and esters thereof, wherein **B** is selected from the groups below:




wherein each of the above shown groups is optionally substituted.

In certain embodiments, the present invention relates to compounds of Formula (I),

and pharmaceutically acceptable salts and esters thereof, wherein R³ is selected from:




In one embodiment, the invention provides a compound represented by Formula (IIa), or (IIb), or a pharmaceutically acceptable salt or ester thereof:



wherein R^3 , R^4 , $\textcircled{\text{B}}$ and X^1 are as previously defined.

5 In another embodiment, the invention provides a compound represented by Formula (IIIa) or (IIIb), or a pharmaceutically acceptable salt or ester thereof:



wherein R^3 and R^4 are as previously defined.

Representative compounds of the invention include, but are not limited to, the
10 following compounds (compound 1 to compound 60 in Table 1) according to Formula (IIIa), and pharmaceutically acceptable salts thereof, wherein R^3 and R^4 are delineated for each compound in Table 1.
















































Table 1

compound	R^3	R^4	compound	R^3	R^4
1			31		
2			32		
3			33		
4			34		

5			35		
6			36		
7			37		
8			38		
9			39		
10			40		
11			41		
12			42		
13			43		
14			44		
15			45		
16			46		

17			47		
18			48		
19			49		
20			50		
21			51		
22			52		
23			53		
24			54		
25			55		
26			56		
27			57		
28			58		

29			59		
30			60		

Representative compounds of the invention include, but are not limited to, the following compounds (compound 61 to compound 120 in Table 2) according to Formula (IIIb), and pharmaceutically acceptable salts thereof, wherein R³ and R⁴ are delineated for each compound in Table 2.


























































































Table 2



compound	R ³	R ⁴	compound	R ³	R ⁴
61			91		
62			92		
63			93		
64			94		
65			95		
66			96		

67			97		
68			98		
69			99		
70			100		
71			101		
72			102		
73			103		
74			104		
75			105		
76			106		
77			107		
78			108		

79			109		
80			110		
81			111		
82			112		
83			113		
84			114		
85			115		
86			116		
87			117		
88			118		
89			119		


90			120		
----	--	--	-----	--	--

In another embodiment, the invention provides a compound represented by Formula (IVa) or (IVb), or a pharmaceutically acceptable salt or ester thereof:



5 wherein R³ and R⁴ are as previously defined.
























Representative compounds of the invention include, but are not limited to, the following compounds (compound 121 to compound 180 in Table 3) according to Formula (IVa), and pharmaceutically acceptable salts thereof, wherein R³ and R⁴ are delineated for each compound in Table 3.























































10

Table 3


compound	R ³	R ⁴	compound	R ³	R ⁴
121			151		
122			152		
123			153		
124			154		
125			155		





















126			156		
127			157		
128			158		
129			159		
130			160		
131			161		
132			162		
133			163		
134			164		
135			165		
136			166		
137			167		









































138			168		
139			169		
140			170		
141			171		
142			172		
143			173		
144			174		
145			175		
146			176		
147			177		
148			178		
149			179		

150			180		
-----	---	---	-----	---	---

Representative compounds of the invention include, but are not limited to, the following compounds (compound 181 to compound 240 in Table 4) and pharmaceutically acceptable salts thereof, according to Formula (IVb), wherein R³ and R⁴ are delineated for each compound in Table 4.


**Table 4**

compound d	R ³	R ⁴	compound d	R ³	R ⁴
181			211		
182			212		
183			213		
184			214		
185			215		
186			216		
187			217		

188			218		
189			219		
190			220		
191			221		
192			222		
193			223		
194			224		
195			225		
196			226		
197			227		
198			228		
199			229		


200			230		
201			231		
202			232		
203			233		
204			234		
205			235		
206			236		
207			237		
208			238		
209			239		
210			240		

In another embodiment, the invention provides a compound represented by Formula (Va) or (Vb), or a pharmaceutically acceptable salt or ester thereof:



wherein R^3 and R^4 are as previously defined.













































5 Representative compounds of the invention include, but are not limited to, the following compounds (compound 241 to compound 300 in Table 5) according to Formula (Va), and pharmaceutically acceptable salts thereof, wherein R^3 and R^4 are delineated for each compound in Table 5.



10


Table 5

compound d	R^3	R^4	compound d	R^3	R^4
241			271		
242			272		
243			273		
244			274		
245			275		
246			276		
247			277		

248			278		
249			279		
250			280		
251			281		
252			282		
253			283		
254			284		
255			285		
256			286		
257			287		
258			288		
259			289		

260			290		
261			291		
262			292		
263			293		
264			294		
265			295		
266			296		
267			297		
268			298		
269			299		
270			300		











































Representative compounds of the invention include, but are not limited to, the following compounds (compound 301 to compound 360 in Table 6) according to Formula (Vb), and pharmaceutically acceptable salts thereof, wherein R^3 and R^4 are delineated for each compound in Table 6.



5




Table 6

compound d	R^3	R^4	compound d	R^3	R^4
301			331		
302			332		
303			333		
304			334		
305			335		
306			336		
307			337		
308			338		
309			339		

310			340		
311			341		
312			342		
313			343		
314			344		
315			345		
316			346		
317			347		
318			348		
319			349		
320			350		
321			351		


322			352		
323			353		
324			354		
325			355		
326			356		
327			357		
328			358		
329			359		
330			360		

In one embodiment, the invention provides a compound represented by Formula (VIa), or (VIb), or (VIc), or a pharmaceutically acceptable salt or ester thereof:




Wherein R^1 , R^2 , R^3 , and X^1 are as previously defined.

In one embodiment, the invention provides a compound represented by Formula (VIIa), or (VIIb), or (VIIc), or a pharmaceutically acceptable salt or ester thereof:



5 Wherein R^1 , R^2 , R^3 , and X^1 are as previously defined.

In one embodiment, the invention provides a compound represented by Formula (VIIIa), or (VIIIb), or a pharmaceutically acceptable salt or ester thereof:



Wherein R^2 , R^3 , R^4 , and X^1 are as previously defined.

10 In certain embodiments, the present invention provides a method for the prevention or treatment of an ASK-1 mediated disease or condition. The method comprises administering a therapeutically effective amount of a compound of Formula (I). The present invention also provides the use of a compound of Formula (I) for the preparation of a medicament for the treatment of an ASK-1 mediated disease or condition.

15 In certain embodiments, the ASK-1 mediated disease or condition is an autoimmune disorder, a neurodegenerative disorder, an inflammatory disease, chronic kidney disease, renal disease, cardiovascular disease, a metabolic disease, or an acute or chronic liver disease.

In certain embodiments, the chronic liver disease is primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced
 20 cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver transplant associated graft versus host disease, living donor transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis,
 25 granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, Sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or alpha 1-antitrypsin deficiency. In certain embodiments, the gastrointestinal disease is inflammatory bowel disease (IBD) (including Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), bacterial overgrowth, malabsorption, post-radiation colitis, or microscopic colitis.

In certain embodiments, the renal disease is diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, or polycystic kidney disease.

5 In certain embodiments, the cardiovascular disease is atherosclerosis, arteriosclerosis, reperfusion/ischemia in stroke, cardiac hypertrophy, respiratory diseases, heart attacks, myocardial ischemia.

In certain embodiments, the metabolic disease is insulin resistance, Type I and Type II diabetes, or obesity.

10 In certain embodiments, the chronic kidney disease is polycystic kidney disease, pyelonephritis, kidney fibrosis and glomerulonephritis.

Yet a further aspect of the present invention is a process of making any of the compounds delineated herein employing any of the synthetic means delineated herein.

15 DEFINITIONS

Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

The term “alkyl” as used herein, refers to saturated, straight- or branched-chain hydrocarbon radicals. “C₁-C₃ alkyl,” “C₁-C₆ alkyl,” “C₁-C₁₀ alkyl,” “C₂-C₄ alkyl,” or “C₃-C₆ alkyl,” refer to alkyl groups containing from one to three, one to six, one to ten carbon atoms, 2 to 4 and 3 to 6 carbon atoms respectively. Examples of C₁-C₈ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, *n*-butyl, *tert*-butyl, neopentyl, *n*-hexyl, heptyl and octyl radicals.

25 The term “alkenyl” as used herein, refers to straight- or branched-chain hydrocarbon radicals having at least one carbon-carbon double bond by the removal of a single hydrogen atom. “C₂-C₁₀ alkenyl,” “C₂-C₈ alkenyl,” “C₂-C₄ alkenyl,” or “C₃-C₆ alkenyl,” refer to alkenyl groups containing from two to ten, two to eight, two to four or three to six carbon atoms respectively. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.

30 The term “alkynyl” as used herein, refers to straight- or branched-chain hydrocarbon radicals having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. “C₂-C₁₀ alkynyl,” “C₂-C₈ alkynyl,” “C₂-C₄ alkynyl,” or “C₃-C₆ alkynyl,” refer to alkynyl groups containing from two to ten, two to eight, two to four or three to six carbon

atoms respectively. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.

The term "cycloalkyl", as used herein, refers to a monocyclic or polycyclic saturated carbocyclic ring or a bi- or tri-cyclic group fused, bridged or spiro system, and the carbon atoms may be optionally oxo-substituted or optionally substituted with exocyclic olefinic, iminic or oximic double bond. Preferred cycloalkyl groups include C₃-C₁₂ cycloalkyl, C₃-C₆ cycloalkyl, C₃-C₈ cycloalkyl and C₄-C₇ cycloalkyl. Examples of C₃-C₁₂ cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 4-methylene-cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.0]hexyl, spiro[2.5]octyl, 3-methylenebicyclo[3.2.1]octyl, spiro[4.4]nonanyl, and the like.

The term "cycloalkenyl", as used herein, refers to monocyclic or polycyclic carbocyclic ring or a bi- or tri-cyclic group fused, bridged or spiro system having at least one carbon-carbon double bond and the carbon atoms may be optionally oxo-substituted or optionally substituted with exocyclic olefinic, iminic or oximic double bond. Preferred cycloalkenyl groups include C₃-C₁₂ cycloalkenyl, C₃-C₈ cycloalkenyl or C₅-C₇ cycloalkenyl groups. Examples of C₃-C₁₂ cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[3.1.0]hex-2-enyl, spiro[2.5]oct-4-enyl, spiro[4.4]non-1-enyl, bicyclo[4.2.1]non-3-en-9-yl, and the like.

The term "aryl," as used herein, refers to a mono- or polycyclic carbocyclic ring system comprising at least one aromatic ring, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, and indenyl. A polycyclic aryl is a polycyclic ring system that comprises at least one aromatic ring. Polycyclic aryls can comprise fused rings, covalently attached rings or a combination thereof.

The term "heteroaryl," as used herein, refers to a mono- or polycyclic aromatic radical having one or more ring atom selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, quinoxalinyl. A polycyclic heteroaryl can comprise fused rings, covalently attached rings or a combination thereof.

In accordance with the invention, aromatic groups can be substituted or unsubstituted.

The term “bicyclic aryl” or “bicyclic heteroaryl” refers to a ring system consisting of two rings wherein at least one ring is aromatic; and the two rings can be fused or covalently attached.

As used herein, the term “arylalkyl” means a functional group wherein an alkylene chain is attached to an aryl group, e.g., $-\text{CH}_2\text{CH}_2\text{-phenyl}$. The term “substituted arylalkyl” means an arylalkyl functional group in which the aryl group is substituted. Similarly, the term “heteroarylalkyl” means a functional group wherein an alkylene chain is attached to a heteroaryl group. The term “substituted heteroarylalkyl” means a heteroarylalkyl functional group in which the heteroaryl group is substituted.

The term “alkylene” as used herein, refers to a diradical of a branched or unbranched saturated hydrocarbon chain, typically having from 1 to 20 carbon atoms (e.g. 1-10 carbon atoms, or 1, 2, 3, 4, 5, or 6 carbon atoms). This term is exemplified by groups such as methylene ($-\text{CH}_2-$), ethylene ($-\text{CH}_2\text{CH}_2-$), the propylene isomers (e.g., $-\text{CH}_2\text{CH}_2\text{CH}_2-$ and $-\text{CH}(\text{CH}_3)\text{CH}_2-$), and the like.

The term “substituted” as used herein, refers to independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to, deuterium, -F, -Cl, -Br, -I, -OH, protected hydroxy, $-\text{NO}_2$, -CN, $-\text{NH}_2$, N_3 , protected amino, alkoxy, thioalkoxy, oxo, $\text{C}_1\text{-C}_{12}\text{-alkyl}$, $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -halo- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -halo- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -halo- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -halo- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -NH- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -NH- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -NH- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -NH- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -NH- aryl, -NH- heteroaryl, -NH- heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -O- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -O- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -O- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -O-aryl, -O- heteroaryl, -O- heterocycloalkyl, -C(O)- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -C(O)- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -C(O)- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -C(O)- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -CONH- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -CONH- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -CONH- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -OCO₂- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -OCO₂- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -OCO₂- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -OCONH- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -OCONH- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -OCONH- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -NHC(O)- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -NHC(O)- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -NHC(O)- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -NHCO₂- $\text{C}_2\text{-C}_{12}\text{-alkenyl}$, -NHCO₂- $\text{C}_2\text{-C}_{12}\text{-alkynyl}$, -NHCO₂- $\text{C}_3\text{-C}_{12}\text{-cycloalkyl}$, -NHCO₂- aryl, -NHCO₂- heteroaryl, -NHCO₂- heterocycloalkyl, -NHC(O)NH₂, -NHC(O)NH- $\text{C}_1\text{-C}_{12}\text{-alkyl}$, -

NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkynyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -
 NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, -
 NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkynyl, -
 NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-
 5 heterocycloalkyl, -NHC(NH)NH₂, -NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-
 alkenyl, -NHC(NH)NH-C₂-C₁₂-alkynyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-
 aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, -NHC(NH)-C₁-C₁₂-alkyl, -
 NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkynyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -
 NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-
 10 alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkynyl, -C(NH)NH-C₃-C₁₂-cycloalkyl,
 -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -
 S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkynyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-
 heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-
 alkenyl, -SO₂NH-C₂-C₁₂-alkynyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-
 15 heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -
 NHSO₂-C₂-C₁₂-alkynyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -
 NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -
 heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -
 methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-
 20 alkynyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, methylthiomethyl,
 or -L'-R', wherein L' is C₁-C₆alkylene, C₂-C₆alkenylene or C₂-C₆alkynylene, and R' is aryl,
 heteroaryl, heterocyclic, C₃-C₁₂cycloalkyl or C₃-C₁₂cycloalkenyl. In certain embodiments,
 the substituents are independently selected from halo, preferably Cl and F; C₁-C₄-alkyl,
 preferably methyl and ethyl; C₂-C₄-alkenyl; halo-C₁-C₄-alkyl, such as fluoromethyl,
 25 difluoromethyl, and trifluoromethyl; halo-C₂-C₄-alkenyl; C₃-C₆-cycloalkyl, such as
 cyclopropyl; -CN; -OH; NH₂; C₁-C₄-alkylamino; di(C₁-C₄-alkyl)amino; and NO₂. It is
 understood that the aryls, heteroaryls, alkyls, and the like can be further substituted. In some
 cases, each substituent in a substituted moiety is additionally optionally substituted with one
 or more groups, each group being independently selected from C₁-C₄-alkyl; CF₃, -F, -Cl, -Br,
 30 -I, -OH, -NO₂, -CN, and -NH₂.

In accordance with the invention, any of the aryls, substituted aryls, heteroaryls and
 substituted heteroaryls described herein, can be any aromatic group. Aromatic groups can be
 substituted or unsubstituted.

It is understood that any alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl moiety described herein can also be an aliphatic group, an alicyclic group or a heterocyclic group. An “aliphatic group” is non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally
5 contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example.
10 Such aliphatic groups may be further substituted. It is understood that aliphatic groups may be used in place of the alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene groups described herein.

The term “alicyclic” as used herein, denotes a monovalent group derived from a monocyclic or polycyclic saturated carbocyclic ring compound by the removal of a single
15 hydrogen atom. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, and bicyclo[2.2.2]octyl. Such alicyclic groups may be further substituted.

As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms
20 connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers. Preferred alkoxy are (C₁-C₃) alkoxy.

The term “aryloxy” refers to the group aryl-O– wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above. The term
25 “arylthio” refers to the group R–S–, where R is as defined for aryl.

The terms “heterocyclic” or “heterocycloalkyl” can be used interchangeably and referred to a non-aromatic ring or a bi- or tri-cyclic group fused, bridged or spiro system, where (i) each ring system contains at least one heteroatom independently selected from oxygen, sulfur and nitrogen, (ii) each ring system can be saturated or unsaturated (iii) the
30 nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (v) any of the above rings may be fused to an aromatic ring, and (vi) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted or optionally substituted with exocyclic olefinic, iminic or oximic double bond. Representative heterocycloalkyl groups include, but are not limited to, 1,3-dioxolane,

pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, 2-azabicyclo[2.2.1]-heptyl, 8-azabicyclo[3.2.1]octyl, 5-azaspiro[2.5]octyl, 1-oxa-7-azaspiro[4.4]nonanyl, 7-oxooxepan-4-yl, and tetrahydrofuryl.

- 5 Such heterocyclic groups may be further substituted. Heteroaryl or heterocyclic groups can be C-attached or N-attached (where possible).

It is understood that any alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic and cycloalkenyl moiety described herein can also be an aliphatic group or an alicyclic group.

- 10 It will be apparent that in various embodiments of the invention, the substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl are intended to be monovalent or divalent. Thus, alkylene, alkenylene, and alkynylene, cycloalkylene, cycloalkenylene, cycloalkynylene, arylalkylene, heteroarylalkylene and heterocycloalkylene groups are to be included in the above definitions, and are applicable to provide the Formulas herein with proper valency.

- 15 The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine and chlorine.

- The term "optionally substituted", as used herein, means that the referenced group may be substituted or unsubstituted. In one embodiment, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In another
20 embodiment, the referenced group is optionally substituted with one or more additional group(s) individually and independently selected from groups described herein.

The term "hydrogen" includes hydrogen and deuterium. In addition, the recitation of an atom includes other isotopes of that atom so long as the resulting compound is pharmaceutically acceptable.

- 25 In certain embodiments, the compounds of each formula herein are defined to include isotopically labelled compounds. An "isotopically labelled compound" is a compound in which at least one atomic position is enriched in a specific isotope of the designated element to a level which is significantly greater than the natural abundance of that isotope. For example, one or more hydrogen atom positions in a compound can be enriched with
30 deuterium to a level which is significantly greater than the natural abundance of deuterium, for example, enrichment to a level of at least 1%, preferably at least 20% or at least 50%. Such a deuterated compound may, for example, be metabolized more slowly than its non-deuterated analog, and therefore exhibit a longer half-life when administered to a subject. Such compounds can synthesize using methods known in the art, for example by employing

deuterated starting materials. Unless stated to the contrary, isotopically labelled compounds are pharmaceutically acceptable.

The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, *et al.*, Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers or *cis*- and *trans*- isomers. Likewise, all tautomeric forms are also intended to be included. Tautomers may be in cyclic or acyclic. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion.

The term "subject" as used herein refers to a mammal. A subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like. Preferably the subject is a human. When the subject is a human, the subject may be referred to herein as a patient.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art.

Berge, *et al.* describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reaction of the free base function with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts e.g., salts of an amino group formed with

inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, 5 alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, 10 persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, *p*-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using 15 counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the term "pharmaceutically acceptable ester" refers to esters which hydrolyze *in vivo* and include those that break down readily in the human body to leave the 20 parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include, but are not limited to, esters of C₁-C₆-alkanoic acids, such as acetate, propionate, butyrate and pivalate esters.

25 The term "hydroxy activating group," as used herein, refers to a labile chemical moiety which is known in the art to activate a hydroxyl group so that it will depart during synthetic procedures such as in a substitution or an elimination reaction. Examples of hydroxyl activating group include, but not limited to, mesylate, tosylate, triflate, *p*-nitrobenzoate, phosphonate and the like.

30 The term "activated hydroxyl," as used herein, refers to a hydroxy group activated with a hydroxyl activating group, as defined above, including mesylate, tosylate, triflate, *p*-nitrobenzoate, phosphonate groups, for example.

The term "hydroxy protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against undesired reactions

during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl
5 protecting groups include benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, tert-butoxy-carbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, allyl, benzyl, triphenyl-methyl (trityl), methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-(trimethylsilyl)-
10 ethoxymethyl, methanesulfonyl, trimethylsilyl, triisopropylsilyl, and the like.

The term "protected hydroxy," as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

The term "hydroxy prodrug group," as used herein, refers to a promoietty group which
15 is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group *in vivo*. Hydroxy prodrug groups as known in the art are described generally in Kenneth B. Sloan, Prodrugs, Topical and Ocular Drug Delivery,
20 (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992) and in "Prodrugs of Alcohols and Phenols" by S. S. Dhareshwar and V. J. Stella, in Prodrugs Challenges and Rewards Part-2, (Biotechnology: Pharmaceutical Aspects), edited by V. J. Stella, et al, Springer and AAPSPress, 2007, pp 31-99.

The term "amino" as used herein, refers to the group $-NH_2$.

25 The term "substituted amino" as used herein, refers to the group $-NRR$ where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl provided that at least one R group is not hydrogen, or a group $-Y-Z$, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl, or alkynyl.

30 The term "amino protecting group" as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic

Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.

5 The term "leaving group" means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxyl, trifluoroacetoxyl and the like.

10 As used herein, the term "pharmaceutically acceptable ester" refers to esters of the compounds formed by the process of the present invention which hydrolyze *in vivo* and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6
15 carbon atoms. Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans
20 and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. "Prodrug", as used herein means a compound, which is convertible *in vivo* by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the Formulae of the instant
25 invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), *Design of Prodrugs*, Elsevier (1985); Widder, *et al.* (ed.), *Methods in Enzymology*, Vol. 4, Academic Press (1985); Krogsgaard-Larsen, *et al.*, (ed). "Design and Application of Prodrugs, *Textbook of Drug Design and Development*, Chapter 5, 113-191 (1991); Bundgaard, *et al.*, *Journal of Drug Deliver Reviews*, 8:1-38(1992); Bundgaard, J. of
30 *Pharmaceutical Sciences*, 77:285 et seq. (1988); Higuchi and Stella (eds.) *Prodrugs as Novel Drug Delivery Systems*, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002).

The term "treating", as used herein, means relieving, lessening, reducing, eliminating, modulating, or ameliorating, i.e. causing regression of the disease state or condition. Treating can also include inhibiting, i.e. arresting the development, of an existing disease state or condition, and relieving or ameliorating, i.e. causing regression of an existing disease state or condition, for example when the disease state or condition may already be present.

The term "preventing", as used herein means, to completely or almost completely stop a disease state or condition, from occurring in a patient or subject, especially when the patient or subject is predisposed to such or at risk of contracting a disease state or condition.

Additionally, the compounds of the present invention, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.

"Solvates" means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H₂O, such combination being able to form one or more hydrate.

As used herein, the term "analog" refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar to or comparable in function and appearance to the reference compound.

The term "aprotic solvent," as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and *N*-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such solvents are well known to those skilled in the art, and individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further

discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: *Organic Solvents Physical Properties and Methods of Purification*, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the *Techniques of Chemistry Series*, John Wiley & Sons, NY, 1986.

5 The terms "protogenic organic solvent" or "protic solvent" as used herein, refer to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known to those skilled in the art, and individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of
10 reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: *Organic Solvents Physical Properties and Methods of Purification*, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the *Techniques of Chemistry Series*, John Wiley & Sons, NY, 1986.

15 Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

20 The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. In addition, the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only
25 and variation of the reaction conditions can produce the desired isoxazole products of the present invention. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein include, for example, those described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*,
30 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995).

 The compounds of this invention may be modified by appending various functionalities via synthetic means delineated herein to enhance selective biological

properties. Such modifications include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

5

PHARMACEUTICAL COMPOSITIONS

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention Formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or Formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered

10

15

tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer

20

solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the Formulator. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally,

25

parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The

30

pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the Formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the Formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular,

intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

The injectable Formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the

drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable Formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragées, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical Formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets

and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and
5 waxes.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be
10 required. Ophthalmic Formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites,
15 silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

20 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

25 Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art. All publications, patents, published patent applications, and other references mentioned herein are hereby incorporated by reference in their entirety.

30 ABBREVIATIONS

Abbreviations which have been used in the descriptions of the schemes and the examples that follow are:

BOP-Cl for bis(2-oxo-3-oxazolidinyl)phosphinic chloride;

CDI for carbonyldiimidazole;

DBU for 1,8-diazabicycloundec-7-ene;
DCC for *N,N'*-dicyclohexylcarbodiimide;
DCM for dichloromethane;
DIPEA for *N,N*-diisopropylethylamine;
5 DMAP for *N,N*-dimethylaminopyridine;
DME for 1,2-dimethoxyethane;
DMF for *N,N*-dimethyl formamide;
DMPU for 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone;
EDC for 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
10 Et₃N for triethylamine;
EtOAc for ethyl acetate;
HATU for 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate;
HCl for hydrochloric acid;
15 *m*CPBA for meta-chloroperoxybenzoic acid;
NMO for *N*-methylmorpholine-*N*-oxide;
PhMe for toluene;
PyAOP for 7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate;
20 PyBOP for benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate;
THF for tetrahydrofuran.


SYNTHETIC METHODS

The compounds and processes of the present invention will be better understood in
25 connection with the following synthetic schemes that illustrate the methods by which the
compounds of the invention may be prepared, which are intended as an illustration only and
not to limit the scope of the invention. Various changes and modifications to the disclosed
embodiments will be apparent to those skilled in the art and such changes and modifications
including, without limitation, those relating to the chemical structures, substituents,
30 derivatives, and/or methods of the invention may be made without departing from the spirit
of the invention and the scope of the appended claims.

As shown in Scheme 1, the compound of Formula (I) can be prepared from coupling
of the carboxylic acid compound (1) and the amine compound (2) under suitable amide


coupling conditions, wherein R^1 , R^2 , R^3 , X^1 , $\textcircled{A}$ and $\textcircled{B}$ are as previously defined. Thus, a mixture of carboxylic acid compound (1) and amine compound (2) in an aprotic solvent is treated with suitable coupling reagent in the presence of organic base to form amide compound of Formula (I). The suitable coupling reagent can be, such as, but not limited to, but is not limited to, BOP-Cl, CDI, DCC, EDC, HATU, PyAOP or PyBOP and the organic base can be, such as, but not limited to, but is not limited to, Et_3N , DIPEA, pyridine or N-methyl morpholine. The aprotic solvent can be, such as, but not limited to, but is not limited to, THF, DCM and DMF. The reaction temperature is from -20°C to 80°C .

Scheme 1



Alternatively, the compound of Formula (I) can also be prepared by first converting carboxylic acid compound (1) to an acid chloride compound (3) and then reacting acid chloride compound (3) with amine compound (2) in the presence of an organic base (as shown in scheme 2).


Scheme 2



Thus, the carboxylic acid compound (1) is treated with thionyl chloride or oxalyl chloride or other acid chloride formation reagent in an aprotic solvent, such as, but not limited to but is not limited to, DCM or DMF, to afford an acid chloride compound (3). Then, the acid chloride compound (3) is reacted with the amine compound (2) in an aprotic solvent, such as, but not limited to DCM or DMF in the presence of an organic base, such as, but not limited to TEA, DIPEA, DMAP or pyridine to give the compound of Formula (I).

Another alternative way to prepare the compound of Formula (I) is by first converting carboxylic acid compound (1) to mixed anhydride compound (4) and then reacting mixed anhydride compound (4) with amine compound (2) in the presence of organic base (as shown in scheme 3).


Scheme 3



Thus, the carboxylic acid compound (1) is treated with a chloroformate reagent such as, but not limited to isobutylchloroformate in an aprotic solvent, such as, but not limited to DCM in the presence of a base such as, but not limited to TEA or DIPEA to afford mixed anhydride compound (4). Then, the mixed anhydride compound (4) is reacted with the amine compound (2) in an aprotic solvent, such as, but not limited to DCM or DMF in the presence of an organic base, such as, but not limited to TEA, DIPEA, or DMAP to give the compound of Formula (I).

Another alternative way to prepare the compound of Formula (I) is to subject carboxylic ester compound (5) and amine compound (2) in AlMe₃-mediated amide formation condition (as shown in scheme 4).


Scheme 4



Thus, the amine compound (2) is first treated with AlMe₃ in an aprotic solvent, such as, but not limited to but is not limited to, DCM, and then reacts with carboxylic ester compound (5) to afford the compound of Formula (I). The reaction temperature is from 0 °C to 80 °C.

Another alternative way to prepare the compound of Formula (I) is to subject compound (6) and amine compound (2) to carbonylation conditions (as shown in scheme 5), wherein X is selected from Cl, Br and I.

Scheme 5




Thus, a mixture of compound (6) and amine compound (2) in an aprotic solvent is treated with suitable catalyst and ligand in the presence of base under CO atmosphere to form amide compound of Formula (I). The suitable catalyst and ligand can be, but is not limited to,

Pd₂dba₃, dppf, Pd(OAc)₂ and dppp. The base can be, but is not limited to, Et₃N, DIPEA, K₂CO₃ or Cs₂CO₃. The aprotic solvent can be, but is not limited to, DMF. The reaction temperature is from 60 °C to 110 °C.

Another alternative way to prepare the compound of Formula (I) is to subject bromide compound (7) and amide compound (8) to cross coupling conditions (as shown in scheme 6).


Scheme 6



Thus, a mixture of bromide compound (7) and amide compound (8) in an aprotic solvent is treated with the suitable combination of catalysts and reagents in the presence of base under blue LED irradiation to form amide compound of Formula (I). The suitable combination of catalysts and reagents can be, but is not limited to, Ir[dF(CF₃)ppy]₂(dtbpy)PF₆ in combination use with NiCl₂·dtbbpy and (Me₃Si)₃SiH. The base can be, but is not limited to, Na₂CO₃ or LiOH. The aprotic solvent can be, but is not limited to, dimethoxyethane or acetonitrile. The reaction temperature is from 20 °C to 50 °C.

Another way to prepare the compound of Formula (I) is to subject boronic ester compound (9) and amide compound (10) to suitable Suzuki cross coupling conditions (as shown in scheme 7), wherein X is selected from Cl, Br and I. The catalyst can be, but is not limited to, Pd(PPh₃)₄, Pd(OAc)₂, Pd(dppf)Cl and Pd₂dba₃. The base can be, but is not limited to, K₂CO₃, Cs₂CO₃ and K₃PO₄. The solvent can be, but is not limited to, dioxane/H₂O, THF/H₂O and DMF. The reaction temperature is from 60 °C to 110 °C.

Scheme 7




EXAMPLES

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents,

derivatives, Formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.

Synthesis of ethyl 2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropane-1-carboxylate (example 1)



Step 1

To a suspension of 5-bromo-2-fluoro-4-methylbenzoic acid (1.5 g, 6.44 mmol) in DCM (21.4 mL) was added Ghosez's reagent (1.02 mL, 7.72 mmol). The reaction was allowed to stir at room temperature for 1 h before concentration under high vac. Then the resulting crude residue was redissolved in DCM (21.4 mL), and then 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (1.31 g, 6.44 mmol) and pyridine (2.1 mL, 25.7 mmol) was added at 0 °C. The reaction was allowed to stir at room temperature for overnight. Direct filtration afforded 1.61 g white solid as compound 3. The filtrate was then concentrated and purified by chromatography on silica gel using 0->5% MeOH in DCM to afford 1.03 g white solid as compound 3 (98% combined yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.90 (s, 1H), 8.89 (s, 1H), 8.19 (dd, J = 8.3, 0.9 Hz, 1H), 8.04 (t, J = 8.0 Hz, 1H), 7.95 – 7.87 (m, 2H), 7.48 (d, J = 10.9 Hz, 1H), 5.65 (p, J = 6.7 Hz, 1H), 2.43 (s, 3H), 1.44 (d, J = 6.7 Hz, 6H).

6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (compound 2) was prepared according to the method disclosed in WO 2016106384.

Step 2


To a microwave vial was charged with compound 3 (1.61 g, 3.86 mmol), ethyl acrylate (1.05 mL, 9.64 mmol), tris(dibenzylideneacetone)dipalladium(0) (177 mg, 0.193 mmol), tri-*o*-tolylphosphine (117 mg, 0.386 mmol) and triethylamine (1.6 mL, 11.57 mmol) in DMF (9.6 mL). The reaction was allowed to stir under microwave irradiation at 100 °C for 1 hour. The crude was then diluted with EtOAc and washed with aq. NH₄Cl, water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by

chromatography on silica gel using 0->10% MeOH in DCM to afford 1.607 g white solid as compound 4 (95% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.90 (s, 1H), 8.87 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 7.3 Hz, 1H), 8.04 (t, J = 8.0 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 15.9 Hz, 1H), 7.34 (d, J = 11.0 Hz, 1H), 6.65 (d, J = 15.8 Hz, 1H), 5.66 (p, J = 6.7 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 2.48 (s, 3H), 1.43 (d, J = 6.7 Hz, 6H), 1.27 (t, J = 7.1 Hz, 3H).

Step 3

To a vial was charged with trimethylsulfonium iodide (425 mg, 1.932 mmol) and sodium hydride (77 mg, 1.932 mmol) in DMSO (2 mL). The resulting suspension was allowed to stir at room temperature for 40 min before addition of a solution of compound 4 (338 mg, 0.773 mmol) in DMSO (1.9 mL). The reaction was allowed to stir at room temperature for 5 hours before carefully quenched with water at 0 °C. The reaction was then diluted with EtOAc, washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->10% MeOH in DCM to afford 241.5 mg white solid as ethyl 2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropane-1-carboxylate (example 1) (69% yield). LC-MS observed [M+H], 452.22, Calcd. 452.21. ¹H NMR (400 MHz, DMSO-d₆) δ 10.75 (s, 1H), 8.87 (s, 1H), 8.20 (d, J = 8.3 Hz, 1H), 8.03 (t, J = 8.0 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.38 (d, J = 7.2 Hz, 1H), 7.25 (d, J = 11.1 Hz, 1H), 5.65 (p, J = 6.7 Hz, 1H), 4.15 (d, J = 7.8 Hz, 2H), 2.46 – 2.36 (m, 1H), 2.41 (s, 3H), 1.90 – 1.81 (m, 1H), 1.47 (t, J = 4.7 Hz, 2H), 1.43 (d, J = 6.7 Hz, 6H), 1.23 (t, J = 7.1 Hz, 3H).

Synthesis of 2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropane-1-carboxylic acid (example 2)




To a solution of example 1 (1.38 g, 3.07 mmol) in THF/H₂O (8 mL/2 mL) was added LiOH (110 mg, 4.60 mmol). The reaction was allowed to stir at 50 °C for 5 hours. The reaction was then cooled to room temperature and acidified by 1 M aq. HCl. The crude residue was extracted with EtOAc (X3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->5% MeOH in DCM to afford 586 mg white solid as 2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropane-1-carboxylic acid

(example 2) (45% yield). LC-MS observed $[M+H]$, 424.19, Calcd. 424.18. 1H NMR (400 MHz, DMSO- d_6) δ 12.38 (s, 1H), 10.74 (s, 1H), 8.87 (s, 1H), 8.19 (d, $J = 8.6$ Hz, 1H), 8.03 (t, $J = 8.0$ Hz, 1H), 7.89 (d, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 7.2$ Hz, 1H), 7.25 (d, $J = 11.2$ Hz, 1H), 5.65 (p, $J = 6.7$ Hz, 1H), 2.42 (s, 3H), 2.40 – 2.36 (m, 1H), 1.78 – 1.66 (m, 1H), 1.43 (d, $J = 6.7$ Hz, 6H), 1.43 – 1.37 (m, 2H).

Synthesis of 5-(2-(cyclopropylcarbamoyl)cyclopropyl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 3)



To a solution of example 2 (18.4 mg, 0.043 mmol) in DMF (0.4 mL) was added cyclopropanamine (5 mg, 0.087 mmol), HATU (33 mg, 0.087 mmol) and DIPEA (23 μ L, 0.13 mmol). The reaction was allowed to stir at room temperature for overnight. The crude was directly purified by chromatography on silica gel using 0->5% MeOH in DCM to afford 12 mg white solid as 5-(2-(cyclopropylcarbamoyl)cyclopropyl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 3) (60% yield). LC-MS observed $[M+H]$, 463.24, Calcd. 463.23. 1H NMR (400 MHz, DMSO- d_6) δ 10.74 (s, 1H), 8.87 (s, 1H), 8.27 (d, $J = 4.2$ Hz, 1H), 8.20 (d, $J = 8.3$ Hz, 1H), 8.03 (t, $J = 7.9$ Hz, 1H), 7.89 (d, $J = 7.6$ Hz, 1H), 7.35 (d, $J = 7.2$ Hz, 1H), 7.23 (d, $J = 11.1$ Hz, 1H), 5.72 – 5.58 (m, 1H), 2.70 – 2.65 (m, 1H), 2.39 (s, 3H), 2.26 – 2.17 (m, 1H), 1.77 – 1.69 (m, 1H), 1.43 (d, $J = 6.8$ Hz, 6H), 1.38 – 1.28 (m, 1H), 1.20 – 1.12 (m, 1H), 0.67 – 0.59 (m, 2H), 0.48 – 0.29 (m, 2H).
Synthesis of tert-butyl (2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropyl)carbamate (example 4)



Step 1

To a suspension of example 2 (523 mg, 1.24 mmol) in toluene (6 mL) was added diphenyl phosphoryl azide (0.53 mL, 2.47 mmol) and triethylamine (0.52 mL, 3.71 mmol). The reaction was allowed to stir at room temperature for 20 hours. The reaction was carefully quenched with aq. $NaHCO_3$ and extracted with EtOAc (X3). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The crude was purified by chromatography on silica gel using 0->5% MeOH in DCM to afford 380.7 mg white solid as

compound 5 (69% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.75 (s, 1H), 8.87 (s, 1H), 8.19 (dd, *J* = 8.3, 0.9 Hz, 1H), 8.03 (t, *J* = 8.0 Hz, 1H), 7.88 (dd, *J* = 7.7, 0.9 Hz, 1H), 7.40 (d, *J* = 7.2 Hz, 1H), 7.26 (d, *J* = 11.1 Hz, 1H), 5.64 (p, *J* = 6.7 Hz, 1H), 2.63 – 2.55 (m, 1H), 2.42 (s, 3H), 1.97 – 1.89 (m, 1H), 1.74 – 1.65 (m, 1H), 1.65 – 1.57 (m, 1H), 1.43 (d, *J* = 6.7 Hz, 6H).


Step 2

A solution of compound 5 (120 mg, 0.268 mmol) in toluene (1.3 mL) was heated at 80 °C for 1 hour before addition of tBuOH (0.26 mL, 2.68 mmol). The reaction was allowed to stir at the same temperature for overnight. The crude was concentrated and purified by

chromatography on silica gel using 0->10% MeOH in DCM to afford 98.7 mg white solid as

tert-butyl (2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropyl)carbamate (example 4) (75% yield). LC-MS observed [M+H], 495.26, Calcd. 495.25. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.70 (s, 1H), 8.86 (s, 1H), 8.20 (d, *J* = 8.3 Hz, 1H), 8.02 (t, *J* = 8.0 Hz, 1H), 7.88 (d, *J* = 7.5 Hz, 1H), 7.31 (s, br, 2H), 7.20 (d, *J* = 11.2 Hz, 1H), 5.65 (p, *J* = 6.8 Hz, 1H), 2.64 – 2.51 (m, 1H), 2.45 (s, 3H), 1.95 – 1.87 (m, 1H), 1.43 (dd, *J* = 6.7, 1.2 Hz, 6H), 1.40 (s, 9H), 1.26 – 1.05 (m, 2H).


Synthesis of 3,3-difluoro-N-(2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-methylphenyl)cyclopropyl)pyrrolidine-1-carboxamide (example 5)



A solution of compound 5 (19.3 mg, 0.043 mmol) in toluene (0.43 mL) was heated at 80 °C for 1 hour before addition of 3,3-difluoropyrrolidine hydrochloride (18.5 mg, 0.129 mmol) and DIPEA (30 μL, 0.172 mmol). The reaction was allowed to stir at the same temperature for overnight. The crude was concentrated and purified by chromatography on silica gel using 0->10% MeOH in DCM to afford 20.8 mg white solid as 3,3-difluoro-N-(2-(4-fluoro-5-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-2-

methylphenyl)cyclopropyl)pyrrolidine-1-carboxamide (example 5) (92% yield). LC-MS observed [M+H], 528.24, Calcd. 528.23. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.70 (s, 1H), 8.86 (d, *J* = 0.9 Hz, 1H), 8.20 (d, *J* = 8.3 Hz, 1H), 8.03 (t, *J* = 8.0 Hz, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.35 (d, *J* = 7.2 Hz, 1H), 7.19 (d, *J* = 11.1 Hz, 1H), 6.72 (d, *J* = 3.5 Hz, 1H), 5.69 – 5.56 (m, 1H), 3.72 – 3.56 (m, 2H), 3.45 (d, *J* = 7.9 Hz, 2H), 2.70 – 2.63 (m, 1H), 2.47 (s, 3H), 2.43 – 2.30 (m, 2H), 1.91 (s, 1H), 1.43 (d, *J* = 6.7 Hz, 6H), 1.28 – 1.12 (m, 2H).

Synthesis of 2-fluoro-5-(2-(4-fluorobenzamido)cyclopropyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 6)




Step 1

- 5 To a solution of example 4 (98.7 mg, 0.20 mmol) in dioxane (0.4 mL) was added 4M HCl in dioxane (0.5 mL, 2.0 mmol). The reaction was allowed to stir at room temperature for overnight. The crude reaction was concentrated and the resulting white solid was directly used in the following transformation. LC-MS observed [M+H], 395.21, Calcd. 395.20.

Step 2

- 10 To a suspension of compound 6 (26 mg, 0.066 mmol) in DCM (0.66 mL) was added DIPEA (69 μ L, 0.396 mmol) and 4-fluorobenzoyl chloride (12.6 mg, 0.079 mmol) at 0 °C. The reaction was allowed to stir at the same temperature for 2 hours. The crude reaction was concentrated and purified by chromatography on silica gel using 0->10% MeOH in DCM to afford 27.4 mg white solid as 2-fluoro-5-(2-(4-fluorobenzamido)cyclopropyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 6) (80% yield).
- 15 LC-MS observed [M+H], 517.22, Calcd. 517.22. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.73 (s, 1H), 8.87 (s, 1H), 8.74 (d, *J* = 4.5 Hz, 1H), 8.21 (d, *J* = 8.2 Hz, 1H), 8.03 (t, *J* = 8.0 Hz, 1H), 7.94 (dd, *J* = 8.8, 5.6 Hz, 2H), 7.89 (d, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.3 Hz, 1H), 7.32 (t, *J* = 8.8 Hz, 2H), 7.23 (d, *J* = 11.2 Hz, 1H), 5.66 (p, *J* = 6.7 Hz, 1H), 3.07 – 2.97 (m, 1H), 2.48 (s, 3H), 2.14 – 2.07 (m, 1H), 1.44 (dd, *J* = 6.7, 1.1 Hz, 6H), 1.41 – 1.29 (m, 2H).
- 20


Synthesis of 5-(2-((N,N-dimethylsulfamoyl)amino)cyclopropyl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 7)



- To a suspension of compound 6 (26 mg, 0.066 mmol) in DCM (0.66 mL) was added DIPEA (69 μ L, 0.396 mmol) and dimethylsulfamoyl chloride (8.5 μ L, 0.079 mmol) at 0 °C. The reaction was allowed to stir at room temperature for 3 days. The crude reaction was concentrated and purified by chromatography on silica gel using 0->10% MeOH in DCM to afford 27.2 mg white solid as 5-(2-((N,N-dimethylsulfamoyl)amino)cyclopropyl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide (example 7) (84%
- 25

yield). LC-MS observed $[M+H]$, 502.21, Calcd. 502.20. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.70 (s, 1H), 8.86 (s, 1H), 8.20 (dd, $J = 8.3, 0.9$ Hz, 1H), 8.02 (t, $J = 8.0$ Hz, 1H), 7.88 (dd, $J = 7.7, 0.9$ Hz, 1H), 7.82 (d, $J = 2.5$ Hz, 1H), 7.25 (d, $J = 7.2$ Hz, 1H), 7.21 (d, $J = 11.2$ Hz, 1H), 5.64 (p, $J = 6.5$ Hz, 1H), 2.72 (s, 6H), 2.61 – 2.57 (m, 1H), 2.47 (s, 3H), 2.20 – 2.09 (m, 1H), 1.43 (dd, $J = 6.7, 0.9$ Hz, 6H), 1.29 – 1.12 (m, 2H).


Synthesis of tert-butyl (2-(2-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-5-methylpyridin-4-yl)cyclopropyl)carbamate (example 8)



Compound 8 was prepared in a similar way as example 4 from commercially available starting material compound 7.

To a solution of compound 8 (34.7 mg, 0.123 mmol) in DMF (0.6 mL) was added compound 2 (52.8 mg, 0.245 mmol), $\text{Pd}(\text{OAc})_2$ (2.8 mg, 0.012 mmol), dppp (10.1 mg, 0.025 mmol) and triethylamine (51 μL , 0.368 mmol). The reaction was purged with CO (X3) and allowed to stir at 80 $^\circ\text{C}$ under 1 atm CO atmosphere for overnight. The crude was diluted with EtOAc, washed with water and brine. The organic layer was dried over Na_2SO_4 , filtered and concentrated. The crude was purified by chromatography on silica gel using 0-100% acetone in hex to afford 4.7 mg white solid tert-butyl (2-(2-((6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)carbamoyl)-5-methylpyridin-4-yl)cyclopropyl)carbamate (example 8) (8% yield). LC-MS observed $[M+H]$, 478.26, Calcd. 478.26.

Synthesis of tert-butyl (R)-(3-(2-((6-(1-(1-hydroxypropan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)carbamoyl)-5-methylpyridin-4-yl)cyclobutyl)carbamate (example 9)



Step 1

To a solution of tert-butyl (3-hydroxycyclobutyl)carbamate (3.98 g, 21.24 mmol) in THF (106 mL) was added PPh_3 (11.14 g, 42.5 mmol) and CBr_4 (42.09 g, 42.5 mmol). The

resulting suspension was allowed to stir at room temperature for 20 hours. The reaction was diluted with 500 mL EtOAc and washed with 10% H₂O₂ (100 mL X2), aq. Na₂SO₃ (100 mL X2) and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was redissolved in EtOH (160 mL) and was charged with a homogeneous solution of zinc chloride (11.58 g, 85 mmol) in warm EtOH (80 mL). The resulting solution was allowed to stir at for 1 hour until precipitation occurred. Filtration. The resulting filtrate was concentrated and purified by chromatography on silica gel using 0->50% EtOAc in hex to afford 2.45 g white solid as compound 10 (46% yield).

Step 2

To an 8 mL vial was charged with photocatalyst Ir[dF(CF₃)ppy]₂(dtbbpy)PF₆ (73 mg, 0.065 mmol), methyl 5-bromo-2-fluoro-4-methylbenzoate (compound 7) (1.348 g, 6.53 mmol), compound 10 (2.45 g, 9.79 mmol), tris(trimethylsilyl)silane (1.691 g, 6.53 mmol) and LiOH (0.313 g, 13.06 mmol) in DME (26 mL). To a separate vial was added NiCl₂·glyme (14.6 mg) and 4,4'-di-*tert*-butyl-2,2'-dipyridine (19 mg). The catalyst vial was sealed, purged with nitrogen, and DME (6 mL) was then added. The precatalyst solution was stirred for 5 minutes, after which, 3 mL of the solution was added into the previous reaction vessel. The reaction solution was then degassed and irradiated with a Kessil blue LED lamp for 20 hours. The crude was diluted with EtOAc, washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->50% EtOAc in hex to afford 1.09 g pale yellow sticky oil as compound 11.

Step 3


To a solution of compound 11 (104.5 mg, 0.352 mmol) in DMF/EtOH (0.88 mL/0.88 mL) was added Pd(OAc)₂ (7.9 mg, 0.035 mmol), dppp (29 mg, 0.070 mmol) and K₂CO₃ (97 mg, 0.704 mmol). The reaction was purged with CO (X3) and allowed to stir at 80 °C under 1 atm CO atmosphere for overnight. The crude was diluted with EtOAc, washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->40% acetone in hex to afford 48.9 mg white solid as compound 12 (42% yield).

Step 4

To a solution of AlMe₃ (2.0 M in toluene solution, 0.24 mL, 0.48 mmol) in DCM (0.4 mL) was added compound 13 (35.6 mg, 0.161 mmol) at 0 °C. The reaction was allowed to stir for 20 min at the same temperature before warm to room temperature for 1 hour. Then a solution of compound 12 (27 mg, 0.081 mmol) in DCM (0.4 mL) was carefully added in the reaction. The resulting reaction was allowed to stir at 40 °C for 18 hours. The reaction was carefully

quenched with 20% Rochelle's salt aq. solution at 0 °C. The aq. layer was extracted by DCM (X2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->50% acetone in hex to afford 15 mg white solid as tert-butyl (R)-(3-(2-((6-(1-(1-hydroxypropan-2-yl)-1H-tetrazol-5-yl)pyridin-2-yl)carbamoyl)-5-methylpyridin-4-yl)cyclobutyl)carbamate (example 9) (37% yield). LC-MS observed [M+H], 509.26, Calcd. 509.26.

Synthesis of (R)-2-(5-(6-aminopyridin-2-yl)-1H-tetrazol-1-yl)propan-1-ol (compound 13) was illustrated as below.



Step 1

TFA (3.2 mL) was added to a solution of (R)-2-((tert-butoxycarbonyl)amino)propyl acetate (992 mg, 4.57 mmol) in DCM (6.5 mL) and the reaction was stirred for 3.5 hrs. The reaction was concentrated under reduced pressure at 45 °C until TFA was removed. Dried oil under vacuum 40 °C give crude (R)-1-acetoxypentan-2-ylammonium 2,2,2-trifluoroacetate as a clear oil that was used without purification: ¹H NMR (400 MHz, DMSO-*d*₆) δ 4.12 (dd, *J* = 11.8, 4.1 Hz, 1H), 4.02 (dd, *J* = 11.8, 7.1 Hz, 1H), 3.55 – 3.41 (m, 1H), 2.06 (s, 3H), 1.18 (d, *J* = 6.7 Hz, 3H).

Step 2

DIPEA (3.1 mL, 17.6 mmol), a solution of (R)-1-acetoxypentan-2-ylammonium 2,2,2-trifluoroacetate (1.1 g, 4.57 mmol) in DMF (5 mL), and HATU (2.0 g, 5.28 mmol) was added to a solution of 6-nitropicolinic acid (592 mg, 3.52 mmol) in DMF (6.73 mL) and the reaction was stirred overnight. The reaction was quenched with H₂O and diluted with EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with water (1x), brine (2x), dried (MgSO₄), filtered, and concentrated under reduced pressure. The resultant yellow gum was purified by column chromatography eluting with hexanes/EtOAc (0% EtOAc → 40% EtOAc) to give (R)-2-(6-nitropicolinamido)propyl acetate (770 mg, 2.88 mmol, 82 % yield) as a yellow gum: ¹H

NMR (400 MHz, Chloroform-*d*) δ 8.57 (dd, $J = 7.7, 1.0$ Hz, 1H), 8.39 (dd, $J = 8.1, 1.0$ Hz, 1H), 8.23 (t, $J = 7.9$ Hz, 1H), 7.92 (d, $J = 8.6$ Hz, 1H), 4.58 – 4.43 (m, 1H), 4.24 (dd, $J = 11.3, 4.4$ Hz, 1H), 4.18 (dd, $J = 11.3, 5.5$ Hz, 1H), 2.11 (s, 3H), 1.36 (d, $J = 6.8$ Hz, 3H).

Step 3

- 5 To a mixture of (R)-2-(6-nitropicolinamido)propyl acetate (765 mg, 2.86 mmol) and sodium azide (298 mg, 4.58 mmol) in acetonitrile (19.1 mL) behind a blast shield at 0 °C was added TiF_2O (4.29 mL, 4.29 mmol, 1.0M solution in DCM) dropwise, and the resulting mixture was stirred for 30 min at 0°C. The cold bath was removed, and the mixture was stirred at rt for 1 h. The reaction was quenched with sat. NaHCO_3 and diluted with EtOAc. The organic layer
- 10 was separated and washed with brine, dried, filtered and concentrated under reduced pressure. The resultant residue was purified by column chromatography eluting with hexanes/EtOAc (0% EtOAc $\rightarrow$ 60% EtOAc) to give (R)-2-(5-(6-nitropyridin-2-yl)-1H-tetrazol-1-yl)propyl acetate (699 mg, 2.392 mmol, 84 % yield) as a pale yellow solid: ^1H NMR (500 MHz, Chloroform-*d*) δ 8.79 (dd, $J = 7.8, 0.9$ Hz, 1H), 8.43 (dd, $J = 8.1, 1.0$ Hz, 1H), 8.32 (dd, $J = 8.4, 7.4$ Hz, 1H), 6.17 (pd, $J = 7.0, 4.5$ Hz, 1H), 4.64 (dd, $J = 11.8, 4.6$ Hz, 1H), 4.59 (dd, $J = 11.7, 7.5$ Hz, 1H), 1.88 (d, $J = 1.0$ Hz, 3H), 1.82 (dd, $J = 6.9, 1.1$ Hz, 3H).
- 15

Step 4

- Pd-C (140 mg, 10% loading) was added to a solution of (R)-2-(5-(6-nitropyridin-2-yl)-1H-tetrazol-1-yl)propyl acetate (699 mg, 2.392 mmol) in MeOH (18.4 mL) and EtOAc (18.4
- 20 mL). The reaction was evacuated and backfilled with H_2 (3x) and the reaction was stirred under a balloon of H_2 overnight. The reaction was filtered through Celite, rinsing with DCM. The filtrate was concentrated under reduced pressure, dissolved in DCM, and filtered through Celite, rinsing with DCM. The filtrate was concentrated under reduced pressure to give (R)-2-(5-(6-aminopyridin-2-yl)-1H-tetrazol-1-yl)propyl acetate (575 mg, 2.192 mmol, 92 %
- 25 yield) as a colorless gum that solidified upon standing: ^1H NMR (500 MHz, Chloroform-*d*) δ 7.67 – 7.60 (comp, 2H), 6.66 (d, $J = 7.0$ Hz, 1H), 6.21 (d, $J = 10.4$ Hz, 1H), 4.67 (dd, $J = 11.4, 4.3$ Hz, 1H), 4.30 (dd, $J = 11.4, 9.4$ Hz, 1H), 1.84 (s, 3H), 1.70 (d, $J = 6.8$ Hz, 3H).






Step 5





- K_2CO_3 (1.1 g, 8.20 mmol) was added to a solution of (R)-2-(5-(6-aminopyridin-2-yl)-1H-tetrazol-1-yl)propyl acetate (430 mg, 1.64 mmol) in MeOH (6.6 mL) and the reaction was
- 30 stirred for 30 min. The reaction was concentrated to remove MeOH and the residue was partitioned between DCM and H_2O . The layers were separated and the aqueous layer was extracted with DCM (3x). The combined organic layers were washed with brine, dried




(MgSO₄), filtered, and concentrated under reduced pressure to give (R)-2-(5-(6-aminopyridin-2-yl)-1H-tetrazol-1-yl)propan-1-ol (compound 13)(327 mg, 1.485 mmol, 91 % yield) as a yellow gum: ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.59 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.27 (dd, *J* = 7.3, 0.8 Hz, 1H), 6.62 (dd, *J* = 8.4, 0.8 Hz, 1H), 6.36 (s, 2H), 5.83 – 5.76 (m, 1H), 4.96 (t, *J* = 5.6 Hz, 1H), 3.80 (ddd, *J* = 11.2, 8.1, 5.9 Hz, 1H), 3.71 (dt, *J* = 11.0, 5.3 Hz, 1H), 1.52 (d, *J* = 6.8 Hz, 3H).

The following examples were prepared by using procedures similar to those described above:


Example	Structure	ESIMS (M-H) ⁻ or (M+H) ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆)
10		521.20	10.71 (s, 1H), 8.86 (s, 1H), 8.23 – 8.13 (m, 2H), 8.02 (t, <i>J</i> = 8.0 Hz, 1H), 7.88 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H), 7.32 (d, <i>J</i> = 7.2 Hz, 1H), 7.21 (d, <i>J</i> = 11.2 Hz, 1H), 5.65 (p, <i>J</i> = 6.7 Hz, 1H), 4.68 (q, <i>J</i> = 9.1 Hz, 2H), 2.73 – 2.66 (m, 1H), 2.46 (s, 3H), 2.09 – 2.00 (m, 1H), 1.43 (d, <i>J</i> = 6.7 Hz, 6H), 1.22 – 1.11 (m, 2H).
11		499.20	
12		513.23	
13		548.24	
14		479.27	10.71 (s, 1H), 8.86 (s, 1H), 8.20 (d, <i>J</i> = 8.3 Hz, 1H), 8.03 (t, <i>J</i> = 8.0 Hz, 1H), 7.88 (d, <i>J</i> = 7.7 Hz, 1H), 7.67 (d, <i>J</i> = 4.6 Hz, 1H), 7.38 (d, <i>J</i> = 7.3 Hz, 1H), 7.20 (d, <i>J</i> = 11.2 Hz, 1H), 5.65 (p, <i>J</i> = 6.7 Hz, 1H), 2.87 – 2.80 (m, 1H), 2.43 (s, 3H), 1.97 – 1.87 (m, 1H), 1.43 (dd, <i>J</i> = 6.6, 1.6 Hz, 6H), 1.22 – 1.08 (m, 2H), 1.11 (s, 9H).

15		435.22	
16		525.25	
17		533.21	
18		560.26	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.57 (s, 1H), 8.90 (s, 1H), 8.33 (dd, <i>J</i> = 8.3, 0.9 Hz, 1H), 8.03 (t, <i>J</i> = 8.0 Hz, 1H), 7.86 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H), 7.63 (s, 1H), 7.12 (s, 1H), 6.67 (d, <i>J</i> = 3.5 Hz, 1H), 5.48 (p, <i>J</i> = 6.7 Hz, 1H), 3.99 (s, 3H), 3.45 (dp, <i>J</i> = 14.1, 7.0 Hz, 2H), 2.82 (s, 3H), 2.67 (dd, <i>J</i> = 4.1, 2.5 Hz, 1H), 2.48 (s, 3H), 2.47 – 2.40 (m, 2H), 1.87 (ddd, <i>J</i> = 9.7, 6.4, 3.5 Hz, 1H), 1.53 (dd, <i>J</i> = 6.7, 1.3 Hz, 6H), 1.20 (dt, <i>J</i> = 9.6, 5.0 Hz, 1H), 1.03 (q, <i>J</i> = 6.4 Hz, 1H).
19		504.20	
20		514.23	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.90 (s, 1H), 8.32 (dd, <i>J</i> = 8.4, 0.9 Hz, 1H), 8.03 (t, <i>J</i> = 8.0 Hz, 1H), 7.86 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H), 7.81 (s, 1H), 7.54 (s, 1H), 7.13 (s, 1H), 5.48 (p, <i>J</i> = 6.8 Hz, 1H), 3.98 (s, 3H), 2.74 (s, 6H), 2.49 (s, 3H), 2.17 – 2.04 (m, 1H), 1.53 (d, <i>J</i> = 6.7 Hz, 6H), 1.23 (dt, <i>J</i> = 9.5, 4.6 Hz, 1H), 1.06 (q, <i>J</i> = 6.5 Hz, 1H).
21		567.20	
22		529.24	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.51 (s, 1H), 8.83 (s, 1H), 8.66 (d, <i>J</i> = 4.7 Hz, 1H), 8.27 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (t, <i>J</i> = 8.0 Hz, 1H), 7.88 (dd, <i>J</i> = 8.7,

			5.6 Hz, 2H), 7.79 (d, $J = 7.6$ Hz, 1H), 7.60 (s, 1H), 7.25 (t, $J = 8.8$ Hz, 2H), 7.08 (s, 1H), 5.42 (p, $J = 6.7$ Hz, 1H), 3.93 (s, 3H), 2.92 (dt, $J = 8.0, 4.0$ Hz, 1H), 2.43 (s, 3H), 2.01 (ddd, $J = 9.8, 6.4, 3.6$ Hz, 1H), 1.46 (d, $J = 6.7$ Hz, 6H), 1.29 (dt, $J = 9.7, 5.1$ Hz, 1H), 1.15 (dt, $J = 7.8, 5.8$ Hz, 1H).
23		491.28	^1H NMR (400 MHz, DMSO- d_6) δ 10.57 (s, 1H), 8.90 (s, 1H), 8.33 (dd, $J = 8.4, 0.9$ Hz, 1H), 8.04 (t, $J = 8.0$ Hz, 1H), 7.86 (dd, $J = 7.6, 0.9$ Hz, 1H), 7.65 (d, $J = 5.2$ Hz, 2H), 7.12 (s, 1H), 5.48 (p, $J = 6.7$ Hz, 1H), 3.99 (s, 3H), 2.79 (dq, $J = 8.5, 4.5$ Hz, 1H), 2.45 (s, 3H), 1.90 (ddd, $J = 9.7, 6.2, 3.6$ Hz, 1H), 1.53 (dd, $J = 6.7, 1.3$ Hz, 6H), 1.25 (dt, $J = 9.6, 5.2$ Hz, 1H), 1.12 (s, 9H), 1.10 – 0.97 (m, 1H).
24		529.22	
25		537.19	^1H NMR (400 MHz, DMSO- d_6) δ 10.71 (s, 1H), 8.80 (s, 1H), 8.29 – 8.14 (m, 2H), 8.05 (t, $J = 8.1$ Hz, 1H), 7.90 (dd, $J = 7.6, 0.9$ Hz, 1H), 7.35 (d, $J = 7.2$ Hz, 1H), 7.24 (d, $J = 11.2$ Hz, 1H), 5.58 (d, $J = 6.5$ Hz, 1H), 4.96 (t, $J = 5.5$ Hz, 1H), 4.71 (q, $J = 9.2$ Hz, 2H), 3.69 – 3.61 (m, 2H), 2.49 (s, 3H), 2.05 (m, 1H), 1.47 (d, $J = 6.9$ Hz, 3H), 1.30 (d, $J = 7.2$ Hz, 1H), 1.26 – 1.15 (m, 1H).
26		564.23	^1H NMR (400 MHz, DMSO- d_6) δ 10.67 (s, 1H), 8.77 (s, 1H), 8.20 (d, $J = 8.3$ Hz, 1H), 8.02 (t, $J = 8.0$ Hz, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.35 (d, $J = 7.2$ Hz, 1H), 7.19 (d, $J = 11.2$ Hz, 1H), 6.69 (d, $J = 3.4$ Hz, 1H), 5.67 – 5.46 (m, 1H), 5.05 – 4.80 (m, 1H), 3.63 (d, $J = 9.6$ Hz, 2H),

			3.46 (m, $J = 7.5$ Hz, 2H), 2.82 (s, 3H), 2.75 – 2.65 (m, 1H), 2.46 (s, 3H), 1.88 (s, 1H), 1.43 (dd, $J = 7.0, 1.4$ Hz, 3H), 1.22 (dt, $J = 9.8, 5.1$ Hz, 1H), 1.14 (q, $J = 6.3$ Hz, 1H).
27		571.17	
28		518.20	^1H NMR (400 MHz, DMSO- d_6) δ 10.67 (s, 1H), 8.77 (s, 1H), 8.19 (d, $J = 8.3$ Hz, 1H), 8.02 (t, $J = 7.9$ Hz, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.82 (s, 1H), 7.23 (dd, $J = 14.3, 9.2$ Hz, 2H), 5.54 (d, $J = 5.6$ Hz, 1H), 4.93 (t, $J = 5.3$ Hz, 1H), 3.62 (d, $J = 5.4$ Hz, 1H), 2.73 (s, 6H), 2.47 (s, 3H), 2.14 (s, 1H), 1.43 (d, $J = 6.9$ Hz, 3H), 1.23 (dd, $J = 9.8, 4.5$ Hz, 1H), 1.18 (d, $J = 6.6$ Hz, 1H).
29		495.25	^1H NMR (400 MHz, DMSO- d_6) δ 10.68 (s, 1H), 8.77 (s, 1H), 8.20 (d, $J = 8.3$ Hz, 1H), 8.02 (t, $J = 8.0$ Hz, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.68 (d, $J = 4.7$ Hz, 1H), 7.38 (d, $J = 5.7$ Hz, 1H), 7.20 (d, $J = 11.2$ Hz, 1H), 5.55 (d, $J = 6.5$ Hz, 1H), 4.93 (t, $J = 5.4$ Hz, 1H), 3.62 (m, 2H), 2.90 – 2.79 (m, 1H), 2.43 (s, 3H), 1.91 (s, 2H), 1.53 – 1.36 (m, 3H), 1.27 (dt, $J = 9.5, 5.1$ Hz, 1H), 1.22 – 1.15 (m, 1H), 1.11 (s, 9H).

Synthesis of example 30 is illustrated in the scheme below:



Step 1

To a solution of commercially available compound 20 (1.25 g, 5.36 mmol) in DCM/tBuOH (10 mL/5 mL) was added Boc anhydride (2.34 g, 10.73 mmol) and DMAP (0.72 g, 5.9 mmol). The reaction was allowed to stir at room temperature for 3 hours. The crude was
5 diluted with EtOAc and washed with aq. NH₄Cl and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->50% EtOAc in hexanes to afford 1.214 g colorless oil as compound 21 (78% yield).
¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (d, *J* = 6.9 Hz, 1H), 7.41 (d, *J* = 11.5 Hz, 1H), 2.39 (s, 3H), 1.54 (d, *J* = 1.0 Hz, 9H).

10 Step 2

To a solution of compound 21 (1.093 g, 3.78 mmol) in dioxane/water (9.45 mL/2.36 mL) was added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.165 g, 7.56 mmol), tetrakis(triphenylphosphine)palladium(0) (0.437 g, 0.378 mmol) and potassium carbonate (1.045 g, 7.56 mmol). The reaction was allowed to stir at 80 °C for 20 hours. The crude was
15 diluted with EtOAc and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->20% MTBE in hexanes to afford 0.624 g colorless oil as compound 22 (70% yield).
¹H NMR (400 MHz, Chloroform-*d*) δ 7.97 (d, *J* = 7.5 Hz, 1H), 6.91 (d, *J* = 11.4 Hz, 1H), 6.85 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.67 (dd, *J* = 17.3, 1.2 Hz, 1H), 5.35 (dt, *J* = 10.9, 0.9 Hz,
20 1H), 2.38 (s, 3H), 1.58 (s, 9H).

Step 3

To a solution of compound 22 (149 mg, 0.631 mmol) and rhodium(II) acetate dimer (13.9 mg, 0.032 mmol) in DCM (3.1 mL) was slowly added ethyl 2-diazoacetate (381 μL, 3.15 mmol) via syring pump over 8 hours at room temperature. The crude was concentrated and
25 purified by chromatography on silica gel using 0->30% EtOAc in hexanes to afford 97.6 mg colorless oil as compound 23 (48% yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.63 (d, *J* = 7.4 Hz, 1H), 6.79 (d, *J* = 11.4 Hz, 1H), 3.81 (qd, *J* = 7.2, 1.2 Hz, 2H), 2.29 (m, 1H), 2.27 (s, 3H), 2.08 (ddd, *J* = 9.1, 8.0, 5.5 Hz, 1H), 1.67 (dt, *J* = 7.5, 5.3 Hz, 1H), 1.51 (s, 9H), 1.33 (td, *J* = 8.2, 5.0 Hz, 1H), 0.93 (t, *J* = 7.1 Hz, 3H).

Step 4

To a solution of compound 23 (257 mg, 0.797 mmol) in DCM (2.8 mL) was added trifluoroacetic acid (0.31 mL, 3.99 mmol). The reaction was allowed to stir at room temperature for 16 hours. The crude was concentrated and purified by chromatography on silica gel using 0->50% EtOAc in hexanes to afford 188 mg white solid as compound 24 (89% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.86 (d, *J* = 7.4 Hz, 1H), 6.97 (d, *J* = 11.5 Hz, 1H), 3.93 (q, *J* = 7.1 Hz, 2H), 2.42 (m, 4H), 2.29 – 2.16 (m, 1H), 1.80 (dt, *J* = 7.6, 5.4 Hz, 1H), 1.47 (td, *J* = 8.3, 5.2 Hz, 1H), 1.03 (t, *J* = 7.1 Hz, 3H).

Step 5

To a suspension of compound 24 (188 mg, 0.706 mmol) in DCM (3.5 mL) was added Ghosez's reagent (112 μ L, 0.847 mmol). The reaction was allowed to stir at room temperature for 1 h before concentration under high vac. Then the resulting crude residue was redissolved in DCM (3.5 mL), and then compound 2 (172 mg, 0.847 mmol) and 2,6-lutidine (329 μ L, 2.82 mmol) was added at 0 °C. The reaction was allowed to stir at room temperature for overnight. The crude was diluted with EtOAc and washed with aq. NH₄Cl and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated. The crude was purified by chromatography on silica gel using 0->10% MeOH in DCM to afford 272 mg white solid as example 30 (85% yield). LC-MS observed [M+H], 452.22, Calcd. 452.21. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.66 (d, *J* = 2.5 Hz, 1H), 8.87 (d, *J* = 0.8 Hz, 1H), 8.21 (dd, *J* = 8.3, 0.9 Hz, 1H), 8.03 (t, *J* = 8.0 Hz, 1H), 7.89 (dd, *J* = 7.6, 0.9 Hz, 1H), 7.51 (d, *J* = 7.4 Hz, 1H), 7.19 (d, *J* = 11.3 Hz, 1H), 5.67 (p, *J* = 6.6 Hz, 1H), 3.85 (qd, *J* = 7.3, 2.1 Hz, 2H), 2.53 (m, 1H), 2.36 (s, 3H), 2.22 (td, *J* = 8.2, 5.2 Hz, 1H), 1.61 (q, *J* = 5.4 Hz, 1H), 1.44 (m, 7H), 1.24 – 1.07 (m, 1H), 0.98 (td, *J* = 7.1, 0.8 Hz, 3H).

25 ASSAYS

The ability (IC₅₀) of compounds to inhibit ASK1 kinase activity was determined by HTRF® KinEASE™ Assay System.

ASK1 was purchased from Thermofisher (Catalogue # PV4011), ATP was purchased from Sigma (Catalogue # A7699), HTRF® KinEASE™ Assay System was obtained from Cisbio (Bedford, Mass). ½ Area plate was purchased from Perkin Elmer (Catalogue # 6005560). HTRF® KinEASE™-STK is a generic method for measuring serine/threonine kinase activities using a time-resolved fluorescence resonance energy transfer (TR-FRET)

immunoassay. The IC₅₀ value for each compound was determined in the presence of compound (various concentration from 0 to 10 μ M) and a fixed amount of ATP and peptide substrates. The test compound, 1 μ M STK3 peptide substrate, and 5 nM of ASK1 kinase are incubated with kinase reaction buffer containing 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, and 1 mM EGTA for 30 minutes. 100 μ M ATP is added to start kinase reaction and incubated for 3 hours. The STK3-antibody labeled with Eu³⁺-Cryptate and 125 nM streptavidin-XL665 are mixed in a single addition with stop reagents provided by the Cisbio kit used to stop the kinase reaction. Fluorescence is detected using an Envision Multilabeled 2014 reader from PerkinElmer. The Fluorescence is measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/ 615nm is calculated for each well. The resulting TR-FRET is proportional to the phosphorylation level. Staurosporine was used as the positive control. IC₅₀ was determined by XLfit 5.3.

By using above method, the inhibition of ASK1 was tested for the compound of formula (I). IC₅₀ ranges are as follows: A < 1 nM; 1 nM < B < 10 nM; C > 10 nM.

Table 7

Example No.	IC50
1	B
2	C
3	C
4	B
5	C
6	C
7	C
8	C
9	C
10	B
11	B
12	C
13	C
14	C
15	B
16	B
17	B
18	B
19	C
20	B
21	B
22	B


23	B
24	B
25	C
26	B
27	B
28	B
29	B
30	C

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the
5 invention encompassed by the appended claims.

CLAIMS


WHAT IS CLAIMED:

1. A compound represented by Formula I or a pharmaceutically acceptable salt thereof:



5 wherein

R₁ is an optionally substituted heteroaryl;



X² and X³ are each independently selected from N or C(R⁵);

R⁵ and R⁶ are each independently selected from the group consisting of:

- 10 1) Hydrogen;
 2) Halogen;
 3) -NO₂;
 4) Cyano;
 5) Optionally substituted -C₁-C₈ alkyl;
 15 6) Optionally substituted -C₃-C₈ cycloalkyl; and
 7) Optionally substituted 3- to 8- membered heterocycloalkyl;

X¹ is N or C(R¹¹), R¹¹ is hydrogen, halogen or optionally substituted alkoxy;

(B) is selected from -C₃-C₈ cycloalkyl and -C₄-C₈ cycloalkenyl, each of which, is optionally substituted with one or more substituents, which are not R³;

20 R² is selected from the group consisting of:

- 1) Hydrogen;
 2) Halogen;
 3) -NO₂;
 4) Cyano;
 25 5) Optionally substituted -C₁-C₈ alkyl;
 6) Optionally substituted -C₂-C₈ alkenyl;
 7) Optionally substituted -C₂-C₈ alkynyl;
 8) Optionally substituted -C₃-C₈ cycloalkyl;
 9) Optionally substituted aryl;

- 10) Optionally substituted arylalkyl;
- 11) Optionally substituted 3- to 8- membered heterocycloalkyl;
- 12) Optionally substituted heteroaryl;
- 13) Optionally substituted heteroarylalkyl;
- 5 14) $-N(R^7)(R^8)$;
- 15) $-S(O)_2N(R^7)(R^8)$;
- 16) $-N(R^7)C(O)(R^8)$;
- 17) $-N(R^7)S(O)_2(R^8)$;


R^3 is selected from the group consisting of:

- 10 1) $-NO_2$;
 - 2) Cyano;
 - 3) $-N(R^7)(R^8)$;
 - 4) $-N(R^9)C(O)N(R^7)(R^8)$;
 - 5) $-N(R^7)C(O)(R^8)$;
 - 15 6) $-N(R^7)C(O)_2(R^8)$;
 - 7) $-N(R^9)S(O)_2N(R^7)(R^8)$;
 - 8) $-N(R^7)S(O)_2(R^8)$;
 - 9) $-C(O)_2(R^7)$;
 - 10) $-C(O)N(R^7)(R^8)$;
 - 20 11) $-C(O)N(R^7)S(O)_2(R^8)$;
 - 12) $-CH_2(O)C(O)_2(R^7)$;
 - 13) $-CH_2(O)C(O)N(R^7)(R^8)$;
 - 14) Optionally substituted $-C_1-C_8$ alkyl;
 - 15) Optionally substituted $-C_2-C_8$ alkenyl;
 - 25 16) Optionally substituted $-C_2-C_8$ alkynyl;
 - 17) Optionally substituted $-C_3-C_8$ cycloalkyl;
 - 18) Optionally substituted aryl;
 - 19) Optionally substituted arylalkyl;
 - 20) Optionally substituted 3- to 8- membered heterocycloalkyl;
 - 30 21) Optionally substituted heteroaryl; and
 - 22) Optionally substituted heteroarylalkyl;
- wherein R^7 , R^8 , and R^9 are independently selected from the group consisting of hydrogen, $-C_1-C_8$ alkyl, $-C_3-C_8$ cycloalkyl, 3- to 8- membered heterocycloalkyl, aryl, and heteroaryl,

all of which are optionally substituted with 1-3 substituents selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, $-\text{CN}$, alkoxy, $-\text{CF}_3$, aryl, and heteroaryl; alternatively, R^7 and R^8 are taken together with the nitrogen to which they are attached to form a heterocyclic.

5


2. The compound of claim 1, wherein R^1 is selected from the following:



wherein R_4 is selected from the group consisting of:


- 1) Hydrogen;
- 2) Optionally substituted $-\text{C}_1-\text{C}_8$ alkyl;
- 3) Optionally substituted $-\text{C}_2-\text{C}_8$ alkenyl;
- 4) Optionally substituted $-\text{C}_2-\text{C}_8$ alkynyl;
- 5) Optionally substituted $-\text{C}_3-\text{C}_8$ cycloalkyl;
- 6) Optionally substituted aryl;
- 7) Optionally substituted arylalkyl;
- 8) Optionally substituted heterocycloalkyl;
- 9) Optionally substituted heteroaryl; and
- 10) Optionally substituted heteroarylalkyl.

3. The compound of claim 1, wherein **B** is selected from the following:




wherein each of the above shown groups is optionally substituted.

4. The compound of claim 1, which is represented by Formula (VIIa), (VIIb), (VIIc), or a pharmaceutically acceptable salt thereof:



wherein R^1 , R^2 , R^3 , and X^1 are as defined in claim 1.


5. The compound of claim 1, which is represented by Formula (IIa), (IIb), or a pharmaceutically acceptable salt thereof:



wherein R^3 , R^4 , B and X^1 are as defined in claim 1.

5


6. The compound of claim 1, which is represented by Formula (VIIIa), (VIIIb), or a pharmaceutically acceptable salt thereof:



wherein R^2 , R^3 , R^4 , and X^1 are as defined in claim 1.

10


7. The compound of claim 1, which represented by Formula (IIIa), (IIIb), (IVa), (IVb), (Va), or (Vb) or a pharmaceutically acceptable salt thereof:



wherein R^3 and R^4 are as defined in claim 1.

15































8. The compound of claim 1, which is selected from compounds of Formula (IIIa) or a pharmaceutically acceptable salt thereof:



wherein R³ and R⁴ are delineated for each compound in Table 1,


Table 1

compound d	R ³	R ⁴	compound d	R ³	R ⁴
1			31		
2			32		
3			33		
4			34		
5			35		
6			36		
7			37		
8			38		
9			39		
10			40		

11			41		
12			42		
13			43		
14			44		
15			45		
16			46		
17			47		
18			48		
19			49		
20			50		
21			51		
22			52		

23			53		
24			54		
25			55		
26			56		
27			57		
28			58		
29			59		
30			60		

9. The compound of claim 1, which is selected from compounds of Formula (IIIb) or a pharmaceutically acceptable salt thereof:













































5

wherein R³ and R⁴ are delineated for each compound in Table 2,


Table 2

compound d	R ³	R ⁴	compound d	R ³	R ⁴
61			91		
62			92		
63			93		
64			94		
65			95		
66			96		
67			97		
68			98		
69			99		
70			100		
71			101		
72			102		

73			103		
74			104		
75			105		
76			106		
77			107		
78			108		
79			109		
80			110		
81			111		
82			112		
83			113		
84			114		
85			115		

86			116		
87			117		
88			118		
89			119		
90			120		

10. The compound of claim 1, which is selected from compounds of Formula (IVa) or a pharmaceutically acceptable salt thereof:






















































































5

wherein R³ and R⁴ are delineated for each compound in Table 3,

Table 3


compound d	R ³	R ⁴	compound d	R ³	R ⁴
121			151		
122			152		

123			153		
124			154		
125			155		
126			156		
127			157		
128			158		
129			159		
130			160		
131			161		
132			162		
133			163		
134			164		

135			165		
136			166		
137			167		
138			168		
139			169		
140			170		
141			171		
142			172		
143			173		
144			174		
145			175		
146			176		

147			177		
148			178		
149			179		
150			180		

11. The compound of claim 1, which is selected from compounds of Formula (IVb) or a pharmaceutically acceptable salt thereof:









































































5

wherein R³ and R⁴ are delineated for each compound in Table 4,

Table 4


compound	R ³	R ⁴	compound	R ³	R ⁴
181			211		
182			212		
183			213		

184			214		
185			215		
186			216		
187			217		
188			218		
189			219		
190			220		
191			221		
192			222		
193			223		
194			224		
195			225		

196			226		
197			227		
198			228		
199			229		
200			230		
201			231		
202			232		
203			233		
204			234		
205			235		
206			236		
207			237		

208			238		
209			239		
210			240		

12. The compound of claim 1, which is selected from compounds of Formula (Va) or a pharmaceutically acceptable salt thereof:





































































5

wherein R³ and R⁴ are delineated for each compound in Table 5,

Table 5


compound	R ³	R ⁴	compound	R ³	R ⁴
241			271		
242			272		
243			273		
244			274		
245			275		

246			276		
247			277		
248			278		
249			279		
250			280		
251			281		
252			282		
253			283		
254			284		
255			285		
256			286		
257			287		

258			288		
259			289		
260			290		
261			291		
262			292		
263			293		
264			294		
265			295		
266			296		
267			297		
268			298		
269			299		

270			300		
-----	--	--	-----	--	--

13. The compound of claim 1, which is selected from compounds of Formula (Vb) or a pharmaceutically acceptable salt thereof:





















































































5














wherein R³ and R⁴ are delineated for each compound in Table 6,

Table 6

compound	R ³	R ⁴	compound	R ³	R ⁴
301			331		
302			332		
303			333		
304			334		
305			335		
306			336		
307			337		

308			338		
309			339		
310			340		
311			341		
312			342		
313			343		
314			344		
315			345		
316			346		
317			347		
318			348		
319			349		

320			350		
321			351		
322			352		
323			353		
324			354		
325			355		
326			356		
327			357		
328			358		
329			359		
330			360		

13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

26	
27	
28	
29	
30	

15. A pharmaceutical composition comprising a compound according to any one of claims 1-14 and a pharmaceutically acceptable carrier or excipient.

5

16. A method for treating an ASK-1 mediated disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-14.

- 10 17. The method according to claim 16, wherein the ASK-1 mediated disease or condition is selected from the group consisting of an autoimmune disorder, a neurodegenerative disorder, an inflammatory disease, chronic kidney disease, renal disease, cardiovascular disease, a metabolic disease, or an acute or chronic liver disease.

- 15 18. The method according to claim 17, wherein the ASK-1 mediated disease or condition is a chronic liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune

hepatitis, chronic viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver transplant associated graft versus host disease, living donor transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, Sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or alpha 1-antitrypsin deficiency.

19. The method according to claim 17, wherein the ASK-1 mediated disease or condition is a renal disease selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, kidney fibrosis and polycystic kidney disease.

20. The method according to claim 17, wherein the ASK-1 mediated disease or condition is a cardiovascular disease selected from the group consisting of atherosclerosis, arteriosclerosis, reperfusion/ischemia in stroke, cardiac hypertrophy, respiratory diseases, heart attacks, myocardial ischemia.

21. The method according to claim 17, wherein the ASK-1 mediated disease or condition is a metabolic disease selected from the group consisting of insulin resistance, Type I and Type II diabetes, and obesity.

22. The method according to claim 17, wherein the ASK-1 mediated disease or condition is a chronic kidney disease selected from the group consisting of polycystic kidney disease, pyelonephritis, kidney fibrosis and glomerulonephritis.

23. A method for treating a disease selected from the group consisting of glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, multiple sclerosis, or Sjogren's syndrome in a

subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-14.

24. A method for treating a disease selected from the group consisting of
5 ischemia/reperfusion in stroke, heart attacks, myocardial ischemia, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, hepatic ischemia, congestive heart failure, pathologic immune responses such as that caused by T cell activation, and thrombin-induced platelet aggregation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-14.

10

25. A method for treating a disease selected from the group consisting of osteoporosis, osteoarthritis and multiple myeloma-related bone disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-14.

15

26. A method for treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), epilepsy, seizures, Huntington's disease, polyglutamine diseases, traumatic brain injury, ischemic and hemorrhaging stroke, cerebral ischemias or neurodegenerative disease, including apoptosis-
20 driven neurodegenerative disease, caused by traumatic injury, acute hypoxia, ischemia or glutamate neurotoxicity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-14.

27. Use of a compound of any one of claims 1-14 in the manufacture of a medicament for
25 treating an ASK-1 mediated disease or condition.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/47423

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Continued Within the Next Supplemental Box

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4, 15/1-4, 16/1-4, 17/16/1-4, 27/1-4

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/47423

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/44; C07D 401/14 (2019.01)

CPC - A61K 31/44; C07D 401/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2011/0009410 A1 (CORKEY, B et al.) 13 January 2011; paragraphs [0009]-[0010], [0014], [0016], [0018]-[0019], [0363], [0401], [0412], [0413], [0433], [0442], [0449]	1-4, 15/1-4, 16/1-4, 17/16/1-4, 27/1-4
Y	WO 2009/011850 A2 (ABBOTT LABORATORIES) 22 January 2009; page 2, lines 25-33; page 3, line 33	1-4, 15/1-4, 16/1-4, 17/16/1-4, 27/1-4



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

"A"

document defining the general state of the art which is not considered to be of particular relevance

"D"

document cited by the applicant in the international application

"E"

earlier application or patent but published on or after the international filing date

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

06 October 2019 (06.10.2019)

Date of mailing of the international search report

03 DEC 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

-Continued from Box No. III Observations where unity of invention is lacking -

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid. Groups I+, Claims 1-27; compound of Formula (I) wherein R1 is an optionally substituted heteroaryl; A is the first shown moiety wherein X2 and X3 are each N and R5 is hydrogen; X1 is N; B is -C3-C8 cycloalkyl; R2 is hydrogen; and R3 is -NO2 (compound structure), and an autoimmune disorder (disease or disorder) are directed to compounds, uses therefor, compositions comprising the compounds, and methods associated therewith.

The compound, uses, compositions and methods will be searched to the extent the compound encompasses a compound of Formula (I) wherein R1 is an optionally substituted heteroaryl; A is the first shown moiety wherein X2 and X3 are each N and R5 is hydrogen; X1 is N; B is -C3-C8 cycloalkyl; R2 is hydrogen; and R3 is -NO2 (first exemplary compound structure) and the disease or disorder encompasses an autoimmune disorder (disease or disorder). Applicant is invited to elect additional compound(s), with fully specified structure thereof (e.g. no optional or variable atoms, bonds or substituents) for each, and/or additional disease(s) or disorder(s), to be searched. Additional compound(s) and/or disease(s) or disorder(s) will be searched upon the payment of additional fees. It is believed that claims 1-4 (each in-part) 15-17 (each in-part), and 27 (in-part) encompass this first named invention and thus these claims will be searched without fee to the extent that they encompass a compound of Formula (I) wherein R1 is an optionally substituted heteroaryl; A is the first shown moiety wherein X2 and X3 are each N and R5 is hydrogen; X1 is N; B is -C3-C8 cycloalkyl; R2 is hydrogen; and R3 is -NO2 (compound structure), and an autoimmune disorder (disease or disorder). Applicants must specify the claims that encompass any additionally elected compound structure(s) and/or disease(s) or disorder(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be a compound of Formula (I) wherein R1 is an optionally substituted heteroaryl; A is the second shown moiety wherein R6 is hydrogen; X1 is N; B is -C3-C8 cycloalkyl; R2 is hydrogen; and R3 is -NO2 (compound structure). Groups I+ share the technical features including: compound represented by Formula I or a pharmaceutically acceptable salt thereof; wherein R1 is an optionally substituted heteroaryl; A is selected from (first heteroaryl moiety) and (second heteroaryl moiety), wherein X2 and X3 are each independently selected from N or C(R5); R5 and R6 are each independently selected from the group consisting of: 1) Hydrogen; 2) Halogen; 3) -NO2; 4) Cyano; 5) Optionally substituted -C1-C8 alkyl; 6) Optionally substituted -C3-C8 cycloalkyl; and 7) Optionally substituted 3- to 8- membered heterocycloalkyl; X1 is N or C(R11), R11 is hydrogen, halogen or optionally substituted alkoxy; B is selected from -C3-C8 cycloalkyl and -C4-C8 cycloalkenyl, each of which, is optionally substituted with one or more substituents, which are not R3; R2 is selected from the group consisting of: 1) Hydrogen; 2) Halogen; 3) -NO2; 4) Cyano; 5) Optionally substituted -C1-C8 alkyl; 6) Optionally substituted -C2-C8 alkenyl; 7) Optionally substituted -C2-C8 alkynyl; 8) Optionally substituted -C3-C8 cycloalkyl; 9) Optionally substituted aryl; 10) Optionally substituted arylalkyl; 11) Optionally substituted 3- to 8- membered heterocycloalkyl; 12) Optionally substituted heteroaryl; 13) Optionally substituted heteroarylalkyl; 14) -N(R7)(R8); 15) -S(O)2N(R7)(R8); 16) -N(R7)C(O)(R8); 17) -N(R7)S(O)2(R8); R3 is selected from the group consisting of: 1) -NO2; 2) Cyano; 3) -N(R7)(R8); 4) -N(R9)C(O)N(R7)(R8); 5) -N(R7)C(O)(R8); 6) -N(R7)C(O)2(R8); 7) -N(R9)S(O)2N(R7)(R8); 8) -N(R7)S(O)2(R8); 9) -C(O)2(R7); 10) -C(O)N(R7)(R8); 11) -C(O)N(R7)S(O)2(R8); 12) -CH2(O)C(O)2(R7); 13) -CH2(O)C(O)N(R7)(R8); 14) Optionally substituted -C1-C8 alkyl; 15) Optionally substituted -C2-C8 alkenyl; 16) Optionally substituted -C2-C8 alkynyl; 17) Optionally substituted -C3-C8 cycloalkyl; 18) Optionally substituted aryl; 19) Optionally substituted arylalkyl; 20) Optionally substituted 3- to 8- membered heterocycloalkyl; 21) Optionally substituted heteroaryl; and 22) Optionally substituted heteroarylalkyl; wherein R7, R8, and R9 are independently selected from the group consisting of hydrogen, -C1-C8 alkyl, -C3-C8 cycloalkyl, 3- to 8- membered heterocycloalkyl, aryl, and heteroaryl, all of which are optionally substituted with 1-3 substituents selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, -CN, alkoxy, -CF3, aryl, and heteroaryl; alternatively, R7 and R8 are taken together with the nitrogen to which they are attached to form a heterocyclic; a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or excipient; a method for treating an ASK-1 mediated disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; a method for treating a disease selected from the group consisting of glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, multiple sclerosis, or Sjogren's syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; a method for treating a disease selected from the group consisting of ischemia/reperfusion in stroke, heart attacks, myocardial ischemia, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, hepatic ischemia, congestive heart failure, pathologic immune responses (such as that caused by T cell activation), and thrombin-induced platelet aggregation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; a method for treating a disease selected from the group consisting of osteoporosis, osteoarthritis and multiple myeloma-related bone disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; a method for treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), epilepsy, seizures, Huntington's disease, polyglutamine diseases, traumatic brain injury, ischemic and hemorrhaging stroke, cerebral ischemias or neurodegenerative disease, including apoptosis-driven neurodegenerative disease, caused by traumatic injury, acute hypoxia, ischemia or glutamate neurotoxicity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; and use of the compound in the manufacture of a medicament for treating an ASK-1 mediated disease or condition. However, these shared technical features are previously disclosed by US 2011/0009410 A1 to Corkey, et al. (hereinafter 'Corkey') in view of WO 2009/011850 A2 (ABBOTT LABORATORIES) (hereinafter 'Abbott'), and further in view of US 2017/0210748 A1 to Calchan Limited (hereinafter 'Calchan').

-Continued Within the Next Supplemental Box-

-Continued from Previous Supplemental Box-

Corkey discloses a compound represented by Formula I: as shown, wherein R1 is an optionally substituted heteroaryl; A is the first shown moiety wherein X2 and X3 are each N and R5 is hydrogen; X1 is N; B is -C3-C8 cycloalkyl; R2 is hydrogen; and R3 is -NO2 (compound of formula I (A is first shown moiety and R1 is optionally substituted heteroaryl) wherein X4, X5 and X8 are each CR4 wherein R4 is hydrogen, X2 and X3 are N, R2 (R5) is hydrogen, X5 (X1) is N, X7 is CR4 wherein R4 (R2) is hydrogen, X6 is CR4 wherein R4 (B) is cycloalkyl substituted by -NO2 (R3 is -NO2); paragraphs [0009]-[0010], [0014], [0016]); a pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier or excipient (pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient; paragraph [0442]); a method for treating an ASK-1 mediated disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound (method of treating ASK-1 mediated diseases or conditions in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound; paragraphs [0009], [0018]-[0019]); a method for treating diabetes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound (a method of treating a metabolic disease, such as diabetes, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound; paragraphs [0018]-[0019], [0433]); a method for treating heart attacks or congestive heart failure in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound (a method of treating a cardiovascular disease, such as myocardial infarctions (heart attacks) and congestive heart failure, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound; paragraphs [0018]-[0019], [0401]); a method for treating a neurodegenerative disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound (method of treating a neurodegenerative disease in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound; paragraphs [0018]-[0019]).

Corkey does not disclose wherein the non-cycloalkyl-substituted meta position of the pyridine ring is unsubstituted. However, Abbott discloses wherein one meta position of a pyridine ring is unsubstituted (compound of formula I wherein Y is N and m is 0 (one meta position unsubstituted); page 2, lines 25-33; page 3, line 33); and a method for treating a disease selected from the group consisting of osteoporosis, osteoarthritis and multiple myeloma-related bone disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound; and use of the compound in the manufacture of a medicament for treating an ASK-1 mediated disease or condition.

Abbott discloses wherein one meta position of a pyridine ring is unsubstituted (compound of formula I wherein Y is N and m is 0 (one meta position unsubstituted); page 2, lines 25-33; page 3, line 33).

Calchan discloses inhibitors of Ask-1, and the use thereof for the prevention or treatment of diseases or disorders or symptoms thereof (inhibitors of Ask-1, and the use thereof for the prevention or treatment of diseases or disorders or symptoms thereof; paragraph [0008]), including rheumatoid and osteoarthritis (including rheumatoid and osteoarthritis; paragraph [0098]); and use of a compound in the manufacture of a medicament for treatment (use of a compound in the manufacture of a medicament for treatment; paragraph [0109]). It would have been obvious to a person of ordinary skill in the art, at the time of the invention, to have modified the compound, as previously disclosed by Corkey, in order to have provided wherein one meta position of a pyridine ring is unsubstituted, as previously disclosed by Abbott; for providing pharmaceutical compositions and compounds useful as kinase inhibitors for the treatment of inflammatory diseases (Abbott; abstract; Corkey; paragraph [0018]). It further would have been obvious to a person of ordinary skill in the art, at the time of the invention, to have modified the disclosure of Corkey to have included the use of the compounds disclosed by Corkey for the treatment of additional disorders treatable with inhibitors of ASK-1, as disclosed by Calchan, including osteoarthritis, in order to provide more effective treatment therefor. It also would have been obvious to a person of ordinary skill in the art, at the time of the invention, to have modified the disclosure of Corkey to have included the use of the compound disclosed by Corkey in the manufacture of a medicament useful for treatment of ASK-1 mediated conditions, as disclosed by Calchan, in order to enable the production of useful pharmaceutical compositions for treatment of said conditions, as disclosed by Corkey.

Since none of the special technical features of the Groups I+ inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by a combination of the Corkey, Abbott and Calchan references, unity of invention is lacking.